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Tribbles (Trib) protein was first described in Drosophila as a regulator of 
proliferation, later being implicated as a G2/M modulator. In mammalian systems, 
three Trib gene family members have been identified, which share a conserved motif 
similar to the catalytic domain of serine/threonine kinases. However, they lack 
several conserved residues in the ATP-binding pocket and the core motif of the 
catalytic domain necessary for catalytic function. Tribbles 1 (Trib1) is involved in 
inflammation through its ability to regulate MAPK, NF-B and the CCAAT 
Enhancer Binding Protein (C/EBP). Moreover, Trib1 is associated with human 
disease, such as atherosclerosis and acute myeloid leukaemia. In this thesis, I 
investigated the functional role of Trib1 in Toll-like Receptor (TLR)-induced 
inflammatory responses together with pro- or anti-inflammatory cytokines. The 
RAW264.7 myeloid cell line was stimulated with TLR2/9 ligands in the presence or 
absence of IFN- or IL-10. I observed a high level of Trib1 expression in the 
presence of IFN- and TLR2 ligands, but weak Trib1 expression following treatment 
with IL-10 and TLR9 ligands. In gene knock-down experiments using small 
interfering RNAs (siRNA) to reduce Trib1 expression, C/EBPβ was up-regulated in 
both stimulated (by IFN- and TLR2 ligands) and resting macrophage populations. 
TNF- production was increased following Trib1 knockdown after treatment with 
IFN- and/or TLR2 ligands but IL-6 secretion remained unchanged. Furthermore, 
ERK1/2 expression was reduced in Trib1 siRNA-treated cells and failed to induce 
chemokinesis in macrophages. Finally, Trib1 was demonstrated to act as a modulator 




The work in this thesis demonstrates that mammalian Trib1 contributes to the 
pro-inflammatory response and functions as a regulator of the ERK1/2 and C/EBPβ 
pathways following TLR ligand-mediated activation. Its novel functions include 
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Chapter 1: General introduction 
    Failure to control inflammatory responses leads to many kinds of diseases. 
Inflammation is triggered not only in response to exogenous stimuli, such as 
pathogens, but also by chronic processes arising from tissue stress and malfunction, 
which now appear to be associated with the pathology of a number of modern 
diseases, including metabolic diseases and atherosclerosis. Innate immunity is the 
first line of host defence against pathogens, and many types of immune cells are 
implicated in this response, such as neutrophils, macrophages and dendritic cells. 
Among these cells, macrophages and dendritic cells are the key components of early 
inflammatory responses of the innate system and control the subsequent activation of 
adaptive immunity. Innate immunity involves not only cellular responses but also 
cytokine families, such as the interferon (IFN) family. Moreover, Toll-Like receptors 
(TLRs) play essential roles in activating downstream components to trigger 
inflammatory responses and then to activate the adaptive immune system. A recently 
discovered gene family, Tribbles, is involved in inflammation, and reports indicate 
that the encoded proteins contribute to chronic inflammatory responses, including 
those associated with atherosclerosis and cancers. However, their functions remain 
ill-defined and research findings are contradictory. Details of the function of Tribbles 
proteins will be presented in the following sections. The goals of this thesis are to 
discover novel roles for Tribbles in macrophages. This introduction provides a 
current review of the literature, and is followed by the general materials and methods 
section and three result chapters containing separate introduction, methods and 
discussion sections. The final chapter summarises and critically reviews the findings 
of this study and indicates future areas of research. 
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1.1 The innate immune system 
    Immunity is defined as resistance to disease, specifically infectious diseases 
(Murphy et al., 2011). Host immune defence consists of two major interacting 
elements, the innate (non-specific) and adaptive (specific) immune systems. Innate 
immunity is the first line of defence against pathogens, including elements such as 
epithelial barriers, and provides protection mediated by both soluble (lysozymes) and 
cellular components (macrophages and neutrophils). Induced innate responses either 
succeed in clearing the infection (by phagocytosis) or hold it until an adaptive 
response develops (through antigen presenting cell (APC)-mediated T cell activation) 
(Boldrick et al., 2002; Janeway et al., 2001; Murphy et al., 2011). 
 
1.1.1 Induced responses of the innate immune system 
    Principle parts of the innate immune response are the cellular components. The 
main cell types involved in this process are macrophages or dendritic cells (DCs) and 
polymorphonuclear leukocytes (PMNs) (Dalton et al., 1993; Janeway et al., 2001). 
Macrophages are continuously differentiated by maturation of circulating monocytes. 
They are attracted by local innate inflammatory mediators and can cross the vascular 
endothelial barrier and migrate to sites of infection. After macrophages, neutrophils 
are the second most important family of phagocytes. Both types of phagocytic cells 
have important direct roles in the innate response because they recognise, ingest and 
destroy pathogens (Gordon, 2003; Janeway et al., 2001). Macrophages migrate to 
areas with active phagocytosis, such as the skin, pulmonary alveoli, lymph node 
sinuses, connective tissues and hepatic sinusoids (Gordon and Taylor, 2005). 
Activated macrophages kill intracellular pathogens by generating nitric oxide and 
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reactive oxygen species. Natural killer (NK) cells develop in the bone marrow from 
the same progenitor cells as T and B lymphocytes and circulate in the blood. They do 
not express T or B cell antigen-specific cell surface receptors, but instead contribute 
to innate host defences through killing virus-infected cells and intracellular pathogen 
by releasing cytotoxic granules, without specific receptor binding (Janeway et al., 
2001). 
    Interactions between pathogens or pathogen products and pattern recognition 
receptors (PRRs), including TLRs, activates various signalling pathways that control 
the response to infections. Subsequently, cells of the innate immune system are 
activated and induce adaptive immune responses, for example T cell responses (Mills 
et al., 2000). Therefore, the innate immune system plays a role in controlling and 
activating the adaptive immune system (Akira et al., 2001; Janeway et al., 2001; 
Murphy et al., 2011). 
    Other components of the humoral innate response provide direct antimicrobial or 
antiviral effects. For example, lysozymes damage bacterial cell walls and type I IFNs 
reduce viral replication within cells. These functions will be addressed in section 
1.2.2 (Janeway et al., 2001; Ubol and Halstead, 2010). 
     
1.1.2 Effector cells involved in the innate immune response: monocytes, 
macrophages and dendritic cells 
    Monocytes differentiate from myeloid lineage progenitor cells in the bone marrow 
before being released into bloodstream. After their release from bone marrow, 
monocytes differentiate into macrophages and migrate into tissues. Many reports 
indicate that IFN- is involved in the macrophage cell cycle and provides a cell 
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survival signal (Gordon, 2003). 
    Migration of macrophages into tissue occurs in response to inflammatory stimuli. 
Tissue resident macrophages generally differentiate from a Gr-1low CX3CR1
high 
CCR2− CD62L− subpopulation of murine monocytes, which are analogous in 
function to CD14+ CD16+ CX3CR1
high CCR2− CD62L− human monocytes (Zhang 
and Mosser, 2008). During the inflammatory response, the dynamics of macrophage 
accumulation dramatically change. A substantial expansion of tissue macrophages 
results from the migration of immature blood monocytes into tissues, where they 
rapidly differentiate into macrophages. These migratory inflammatory macrophages 
typically form a Gr-1high CX3CR1
low CCR2+ CD62L+ subpopulation in mice, with a 
similar function to CD14high CD16− CX3CR1
low CCR2+ CD62L+ human cells (Zhang 
and Mosser, 2008) (Fig. 1.1). 
    The heterogeneity of monocytes reflects their function specialisation in different 
anatomical locations. For example, macrophages from the alveolar region are distinct 
from thymic macrophages. There is a high level of pattern recognition receptor and 
scavenger receptor (SR) expression by alveolar macrophages, which are involved in 
clearing microorganisms, viruses and environmental particles within the lungs, 
whereas thymic macrophages function in the germinal centre to clear apoptotic 
lymphocytes generated during development of an acquired immune response 
(Gordon and Taylor, 2005). 
    Many transcription factors are involved in monocyte–macrophage differentiation. 
For example, PU.1 induces expression of the macrophage colony-stimulating factor 
receptor (Valledor et al., 1998). Monocytic precursor cells recognizing macrophage 
colony-stimulating factor survive, proliferate and mature into monocytes. Moreover, 
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mature monocyte or macrophage phenotypes, such as the expression of CD11b, 
CD14 and CD18 and scavenger receptors, are regulated by PU.1 (Valledor et al., 
1998). In addition, macrophages express many cell surface receptors, such as SRs, 
which internalise modified low-density lipoprotein (LDL); mannose receptors, which 
recognise sugar components; and β-glucan receptors, which bind to apoptotic cells 
and invading pathogens and internalise them by phagocytosis (Gordon, 2003). 
     
                   
Figure 1.1. Development and function of monocyte subpopulations in mice. Resting 
monocytes, Gr-1low CX3CR1high CCR2− CD62L−, originate from the bone marrow. After 
stimulation by antigens, most inflammatory monocytes differentiate into macrophages, 
characterised as Gr-1high CX3CR1low CCR2+ CD62L+. Mature monocytes express 



















    DCs were discovered in 1973 by Steinman and Cohn, and were later identified as a 
group of immune cells important for both innate and adaptive immunity (Steinman 
and Cohn, 1973). DCs derive from both myeloid and lymphoid progenitors within 
the bone marrow and migrate via blood to tissues throughout the body and to 
peripheral lymphoid organs. Immature DCs reside in the epithelia of skin and 
mucosal tissues. They are characterised by a high endocytic function and low levels 
of surface histocompatibility complex class (MHC) and co-stimulatory molecules. 
Immature DCs do not directly kill microbes. During pathogen stimulation of 
immature DCs, surface MHC and co-stimulatory molecules are up-regulated. Two 
types of DCs exist: conventional and plasmacytoid. The main role of conventional 
DCs is to generate antigens that activate T cells, while plasmacytoid DCs are the 
main producers of antiviral interferons (Banchereau and Steinman, 1998). 
    Therefore, macrophages and DCs work to link innate and adaptive immunity. 
 
1.1.3 Macrophage classification 
    The inflammatory environment affects macrophage differentiation, and the 
presence of certain cytokines regulates the phenotype and function of differentiated 
macrophages. Macrophages activated by TLRs and by IFN- induction are termed 
M1-type cells (Farrar and Schreiber, 1993; McCoy and O'Neill, 2008; Medzhitov, 
2001). In contrast, macrophages exposed to Th2 cytokines, such as IL-4 and IL-13, 
or IL-10 and glucocorticoids have an alternatively activated phenotype (M2-type), 
characterised by a reduced ability to destroy intracellular bacteria. However, M2-type 
macrophages appear to function in the resolution of infection and in wound healing 
(Mantovani et al., 2002; Mills et al., 2000; Mosser, 2003; Sica et al., 2008; Solinas et 
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al., 2009) (Fig. 1.2). IL-10 inhibits the production of pro-inflammatory cytokines, 
such as TNF-, IL-6 and IL-12, in macrophages and inhibits antigen presentation by 
monocytes or macrophages by down-regulation of MHC II and co-stimulatory 
molecules (Haddad et al., 2003; Moore et al., 2001). 
 
   
Figure 1.2. Polarisation of macrophage functions. Macrophages constitute an extremely 
heterogeneous cell population, which can be divided into two main classes: M1 and M2. M1 
macrophages function in bacterial defence, tumour suppression and immunostimulation, 
whereas M2 macrophages are important in tissue repair and tumour progression. 
 
1.1.4 Tumour-associated macrophages 
    In recent years, evidence has accumulated that macrophages play an important role 
in promoting tumour growth, progression and metastasis (Pollard, 2004). Indeed, 
similar to the different subtypes of resident tissue macrophages, macrophages 
residing in the tumour microenvironment exhibit distinct phenotypes and have been 
named tumour-associated macrophages (TAMs) (Gordon, 2003; Pollard, 2004). They 
have M2-phenotypes and contribute to a general suppression of antitumor activities 

























1.1.5 Potential functions of monocytes, macrophage and dendritic cells 
    The recruitment of monocytes and neutrophils from the blood to sites of 
inflammation is one of the most important functions of innate immunity. Recruitment 
of these cells takes place as part of the inflammatory response and is mediated by the 
expression of cell adhesion molecules on the surface of the endothelial cells of local 
blood vessels. Tissue macrophages provide an immediate defence against foreign 
pathogens and coordinate leukocyte infiltration (Martinez et al., 2008). Adhesion and 
migration characterise both monocytes and macrophages. During inflammation, 
monocytes and neutrophils bind to adhesion molecules on endothelial cells and 
migrate into inflamed tissues where monocytes differentiate into macrophages 
(Juliano and Haskill, 1993). Intercellular adhesion molecule-1 (ICAM-1) is 
expressed on endothelium, epithelium and APCs (Janeway et al., 2001). In addition 
to its role in cell adhesion, ICAM-1 contributes to monocyte–macrophage 
differentiation in inflamed tissues (Coccia et al., 1999). 
    Monocytes can differentiate into either macrophages or DCs, both of which are 
professional APCs (Janeway et al., 2001; Zhang and Mosser, 2008). DCs are more 
efficient APCs than macrophages because they constitutively express higher levels of 
cell surface markers than macrophages do. As a result, they rapidly capture antigens 
and transport them to lymph nodes. In addition, DCs are the major providers of MHC 




1.2 Signalling pathways in innate immunity 
    Cells of the immune system sense their environment and communicate with other 
cells using many different types of cell surface receptors. For example, Toll-like 
receptors (TLRs) detect microbial infection: pathogens ligate to immune TLRs 
present on the cell surface (TLR4) or on intracellular endosomes (TLR3). Interferons 
are produced by virus infected cells in response to viral infection and contribute to 
the innate antiviral defence mechanism. 
1.2.1 Toll-like receptors (TLRs) 
    The involvement of Toll receptors in innate immunity was first described in the 
fruit fly, Drosophila melanogaster. Drosophila Toll was originally reported to 
establish dorso–ventral polarity during embryonic development but is also known to 
function in immunity (Belvin and Anderson, 1996; Medzhitov, 2001; O'Neill, 2004; 
Takeda et al., 2003). Hultmark first identified Toll as an activator of the immune 
response in a Drosophila cell line (Rosetto et al., 1995). Drosophila uses the Toll 
pathway to respond to Gram-positive bacterial and fungal infection (Belvin and 
Anderson, 1996). In contrast to Drosophila Toll, mammalian TLRs are not thought 
to be involved in development (Kimbrell and Beutler, 2001). Mammalian TLRs are 
type I transmembrane proteins that recognise most pathogenic microbes and are 
characterised by an extracellular domain containing leucine-rich repeats, a 
transmembrane region and an intracellular Toll/IL-1 receptor homology domain. 
TLRs are expressed by innate immune cells (dendritic cells, macrophages, NK cells), 
cells of the adaptive immune response (B lymphocytes) and non-immune cells 
(epithelial and endothelial cells, fibroblasts) (Medzhitov, 2001; Takeuchi and Akira, 
2010). However, TLRs have limited specificity compared with antigen receptors of 
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the adaptive immune system. Stimulation of TLRs on cells of the innate immune 
system activates signalling pathways that initiate immune responses and 
inflammation as part of the antimicrobial response. 
    TLRs can bind to different ligands, including bacterial cell wall components, viral 
double-stranded RNA and immunomodulatory compounds (Takeda et al., 2003). 
Based on their primary sequences, TLRs can be further classified into several 
categories depending on their recognition of pathogen-associated molecular patterns 
(PAMPs): the TLR1, TLR2 and TLR6 subfamily recognises lipoproteins; the closely 
related TLR7, TLR8 and TLR9 subfamily recognises nucleic acids (Akira et al., 
2006). TLR1, TLR2, TLR4, TLR5 and TLR6 are expressed on the cell surface and 
TLR3, TLR7, TLR8 and TLR9 are expressed exclusively in intracellular 
compartments, such as endosomes, and their ligands, mainly nucleic acids, require 
internalisation to the endosome before TLR binding can be achieved (Krishnan et al., 
2007). Ten TLRs have been reported in humans and 11 in mice. However, the ligand 




Table 1.1. TLRs and their ligands 
TLR Location 

















/ bacteria, viruses, 
parasites 
Monocytes/macrophages, 
DCs, mast cells, eosinophils 




LPS / bacteria, 
viruses 














Plasmacytoid DCs, NK cells, 
eosinophils, B cells 
TLR9 Endosome 
CpG DNA / virus, 
bacteria, protozoa 
Plasmacytoid DCs, 
eosinophils, B cells 
TLR10 Endosome Unknown 
Plasmacytoid DCs, 








Macrophages, DCs, liver, 
kidney, bladder epithelial cells 
This table was modified from Janeway’s Immunobiology (Murphy et al., 2011). 
 
1.2.1.1 TLRs and innate immunity 
    TLRs play a central role in the immune response by detecting invading pathogens, 
triggering the initiation of innate immunity and helping to strengthen adaptive 
immunity (Akira et al., 2006; Medzhitov, 2001; Takeuchi and Akira, 2010). Innate 
recognition of PAMPs by TLRs initiates a signalling cascade that results in 
transcription of many immune and inflammatory genes. As well as initiating an 
innate immune response, there is increasing evidence to suggest that TLRs also play 
a role in other macrophage functions, such as phagocytosis, antigen processing, 
presentation and initiating the adaptive immune response (McCoy and O'Neill, 2008; 
Pasare and Medzhitov, 2004; Schnare et al., 2001). Macrophages express most of the 
ten TLRs (summarised in Table 1.1; (McCoy and O'Neill, 2008). In an early study, 
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mRNA expression of TLRs 1–5 was analysed in a human leukocyte population 
containing monocytes, T lymphocytes, NK cells, DCs and granulocytes (Alan, 2001; 
McCoy and O'Neill, 2008). TLR1 was expressed on all of these cell types, whereas 
TLR2, TLR4 and TLR5 were expressed on monocytes or macrophages, DCs and 
granulocytes (Alan, 2001; McCoy and O'Neill, 2008). In contrast, TLR3 is expressed 
on DCs, NK cells and plays an important role in the antiviral immune responses by 
producing type I IFNs (Funami et al., 2004; Muzio et al., 2000). TLR4 is expressed 
on monocytes and macrophages in both humans and mice. TLR9 is constitutively 
expressed on DCs and has an essential role in antiviral immunity (Ashkar and 
Rosenthal, 2002; Kato et al., 2005; Wan et al., 2011). Sequence analysis indicates 
that TLR10 is related to TLR1 and TLR6. Mice do not express TLR10, but they 
express additional TLRs that are absent in humans, such as TLR11 (Takeuchi and 
Akira, 2010), which is similar to TLR5 and is expressed in response to protozoan 
infection (Pifer et al., 2011). 
    Among TLR family members, TLR2 and TLR4 have been most intensely studied 
as they are regarded to be the major transmembrane TLRs. TLR2 identifies 
lipoteichoic acid (LTA) and lipoproteins from a variety of Gram-positive and Gram-
negative bacteria, mycobacteria and fungi. Stimulation through TLR2 induces the 
expression of specific transcripts for pro-inflammatory cytokines. Moreover, TLR2 
forms heterodimers with TLR1 or TLR6 detect specific lipid components of 
lipoproteins. For instance, TLR2–TLR1 heterodimers recognise triacyl lipopeptides, 
whereas TLR2–TLR6 heterodimers recognise diacyl lipopeptides (Kaisho and Akira, 
2006; Liu et al., 2006; Santos-Sierra et al., 2009; Takeuchi et al., 2001). Stimulation 
of TLR2 by, for example, diacyl lipoproteins in macrophages and DCs, induces the 
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production of pro-inflammatory cytokines. TLR2 expression has been reported to 
induce type I IFNs in monocytes in response to viral infection (Barbalat et al., 2009). 
Therefore, the cellular responses to TLR2 differ depending on cell type.  Furthermore, 
TLR2 plays a key role in the macrophage response to streptococcus species and 
Mycobacterium tuberculosis in mouse disease models and in humans (Draper et al., 
2006; McBride, 2010; Sabroe et al., 2008). The C-terminus of TLR2 also participates 
in anti-fungal and anti-protozoan immunity (Gazzinelli et al., 2004; Simitsopoulou et 
al., 2008). 
    TLR4 is the best-studied TLR and was the first to be identified (Akira, 2003; 
Kaisho and Akira, 2001). TLR4 recognises LPS and the myeloid differentiation 2 
(MD2) adaptor protein and its co-receptor CD14 (Kaisho and Akira, 2001). 
Stimulation with LPS activates macrophages and triggers downstream production of 
inflammatory cytokines, such as IL-1, IL-6 and TNF- (Kaisho and Akira, 2001). 
Interestingly, TLR4 recognises not only bacterial components but also viral proteins 
such as a fusion protein from the Respiratory syncytial virus (Kurt-Jones et al., 2000; 
Uematsu and Akira, 2007). Additionally, TLR4 was reported to regulate the 
pathogenesis of Influenza virus (H5N1)-induced acute lung injury (Imai et al., 2008). 
 
1.2.1.2 TLR signalling pathways 
    TLR signalling, regardless of which receptor is stimulated, results in the activation 
of NF-B and downstream regulatory responses (Fig. 1.3). TLR3, TLR7 and TLR8 
also mediate the activation of IFN gene regulatory factor-3 (IRF3) and IRF7 to 
trigger type 1 IFN induction (Akira et al., 2006; Kaisho and Akira, 2001). The 
signalling events initiated by TLR activation are mediated by a unique interaction 
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between Toll/IL-1 receptor (TIR) domain-containing cytosolic adaptors, including 
myeloid differentiation primary response protein 88 (MyD88), the TIR domain-
containing adaptor protein (TIRAP), the TIR domain-containing adaptor-inducing 
IFN- (TRIF) and the TRIF-related adapter molecule (TRAM) (Akira et al., 2006; 
Kaisho and Akira, 2001). MyD88 is the central adaptor protein associated with      
IL-1R-assaociated kinase (IRAK) 4, which in turn recruits and phosphorylates 
IRAK1 and IRAK2. Following interaction with	 TNF receptor associated factor-6 
(TRAF6), the activated IRAK complex phosphorylates TAB1 and TAK1, which then 
activate NF-B and mitogen-activated protein kinase (MAPK) pathways that mediate 
inflammatory responses through expression of pro-inflammatory cytokines (IL-1, 
IL-6, IL-8, IL-12 and TNF-) and macrophage inflammatory proteins (MIP and 
MIP) (Akira, 2003; Takeuchi and Akira, 2010). 
    Recently, two CCAAT/enhancer-binding proteins (C/EBPs) family members have 
been reported to have roles in TLR-induced downstream signalling. In addition to 
their roles in conventional MyD88/TRAF/NF-B signalling, C/EBPs  and  are 
important transcription factors in a MyD88-dependent pathway that regulates the 






Figure 1.3. TIR-containing adaptors in TLR signalling. TLR signalling is divided into two 
main pathways: MyD88-dependent and MyD88-independent. Therefore, the MyD88 adaptor 
molecule is the key mediator of TLR signalling. The MyD88-dependent pathway is used by 
all TLRs except for TLR3. TLR7, TLR8 and TLR9 interact directly with MyD88 following 
ligand binding, while TLR4 and TLR2 (which forms a heterodimer with either TLR1 or 
TLR6) bind to the bridging adaptor Mal in order to recruit MyD88. Following MyD88 
recruitment to activated TLRs stimulates the binding of IRAKs (IRAK1/4). IRAKs then 
activate TRAF6, which in turn activates the IKK complex, leading to phosphorylation and 
subsequent degradation of . This process induces nuclear translocation of NF-B and the 
induction of inflammatory cytokines. Activation of TLR7, TLR8 and TLR9 lead to the 
nuclear translocation of IRF-7, resulting in type I IFN expression. In contrast, the MyD88-
independent pathway is only used by TLR3 and TLR4, and involves the TIR-adaptor 
molecule, TRIF. TRIF activates TBK1, which causes activation and nuclear translocation of 
IRF-3, resulting in type I IFN production. Similar to the MyD88-dependent pathway, TLR4 
signalling via the MyD88-independent pathway requires a bridging adaptor, in this case 
TRAM. The MyD88-independent pathway leads to NF-B activation via TRIF activation 



















































                                   
Figure 1.4. The TLR2 signalling pathway is regulated by C/EBPs  and . In addition to the 
well-known TLR2 signalling cascade (MyD88/TRAF/NF-B), CEBPs  and  transcription 
factors can mediate pro-inflammatory cytokine production. MyD88 recruited to activated 





















1.2.2 Type I and type II IFNs 
    Viral infection induces the expression of interferon proteins (IFNs), which 
interfere with viral replication. There are two types of IFNs: IFNs- and  are type I 
IFNs and were first described over 50 years ago, while IFN- is a type II IFN. IFN- 
and IFN- are produced at the early stages of viral infection and have important roles 
in the response to intracellular pathogens (Murphy et al., 2011; Trinchieri, 2010). 
Most type I IFNs are believed to be secreted by plasmacytoid DCs. Plasmacytoid 
DCs express the intracellular endosomal receptors TLR7 and TLR9 in response to 
single-stranded RNA and DNA viruses, respectively, by triggering signal 
transduction through MyD88 and inducing the downstream production of  IFN-/ 
via IRF7 (see Fig. 1.3) (Colonna et al., 2004; Trinchieri, 2010). Therefore, IFN-/ 
plays a key role in DC maturation and differentiation, and in B cell activation 
(Christian, 2000; Montoya et al., 2002). Later studies indicated that IFN-/ directly 
suppress viral replication and protect APCs from viral infections (Zhang et al., 2008). 
    IFN- is distinct from type I IFNs at both the genetic and protein levels (Farrar and 
Schreiber, 1993). IFN- is secreted by CD4+ T helper cell type 1 (Th1) lymphocytes, 
CD8+ cytotoxic lymphocytes and NK cells. Recent evidence indicates that other cells, 
such as B cells and NKT cells, also produce IFN- (Murphy et al., 2011). IFN- 
secretion by APCs is likely to be an important early host defence against infection. 
For instance, IFN- secretion results in increased expression of MHC class I and II 
molecules on APCs, whereas T cells are the major source of IFN- in the adaptive 





1.2.2.1 IFNs and activated macrophages 
    Macrophages are an important cellular source of IFNs in the immune system. 
Previous studies indicated that low level constitutive expression of IFN- occurs in 
resting macrophages, and that macrophage IFN- expression is up-regulated 
following viral infection and is stimulated by dsRNA or exposure to microbial 
products (Christian, 2000). In contrast, IL-4 and IL-10 suppress the production of 
IFN- in mouse and human macrophages (Christian, 2000). 
    More importantly, pathogen-induced IFN- is a potent macrophage activator that 
orchestrates leukocyte recruitment and regulates the growth, maturation and 
differentiation of many cell types (Christian, 2000; Farrar and Schreiber, 1993). 
Classical activation of macrophages by IFN- is mediated by Signal Transduction 
and Activation of Transcription-1 (STAT1) signalling and comprises two essential 
aspects of macrophage function, antigen processing and presentation, as well as 
antimicrobial and antiviral effector mechanisms. For instance, the transporter 
associated with antigen processing (TAP) gene and the MHC heavy chains (2-
microglobulin) are direct up-regulated during antigen presentation mediated by 
STAT-1 (Briscoe et al., 1996; Pestka et al., 1997; Schroder et al., 2006). To 
efficiently kill intracellular pathogens, such as mycobacteria, macrophages need help 
from the adaptive immune system, mainly in the form of IFN- provided by T cells 
(Hickman et al., 2002; Lang, 2005). 
 
1.2.2.2 General principles of IFN signalling pathways 
    IFN- and IFN- both initiate the Janus kinase (JAK)–STAT signalling pathway, 
but involve different components (Briscoe et al., 1996; Ramana et al., 2001); (Figs. 
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1.5 and 1.6). The IFN--induced JAK–STAT1 signalling regulates macrophage 
activation and function. IFN- binding to the IFNGR cell surface receptor leads to 
tyrosine phosphorylation and activation of JAK kinases 1 and 2, which facilitates 
transphosphorylation of both JAKs and receptor subunits. STAT1 is then recruited to 
the receptor and becomes phosphorylated on Tyrosine701, enabling STAT1 to 
homodimerise (Briscoe et al., 1996; Wen et al., 1995). The STAT1 homodimer 
translocates to the nucleus, binds to transcription factor response elements, such as 
the Gamma-Activated Sequence (GAS) in target gene promoters, and initiates 
transcription (Decker et al., 1997). IFN- predominantly activates STAT1, which 
mediates enhanced microbial killing by IFN- by increasing MHC class I and II 
expression and inflammatory cytokine production (Chatterjee-Kishore et al., 2000; 
Hu et al., 2008). AP-1 transcription factors are rapidly activated by IFN- 
independent of JAK1/2 and STAT-1 (Gough et al., 2007). 
    IFN- binding to IFNAR 1 and 2 cell surface receptors similarly leads to 
receptor-associated JAK kinase 1 and 2 activation and tyrosine kinase 2 (Tyk2) 
phosphorylation, and transphosphorylation of JAKs and receptor subunits. 
Subsequently, cytoplasmic STAT1 and STAT2 are phosphorylated by JAK and Tyk2 
respectively, translocated to the nucleus, bind to transcription factor-binding 
sequences, such as the IRF7 and ISRE (IFN-stimulated response element) response 






                   
Figure 1.5. The IFN- signalling cascade. IFN- binds to IFNGR and JAK/TYK2, which are 
then phosphorylated. Subsequently, STAT-1 becomes phosphorylated at Tyr701 and is 
translocated to the nucleus, where it binds to ISRE and GAS (ISRE/GAS) response elements 






















                        
Figure 1.6. IFN- signalling and target gene activation. IFN- bind to IFNAR1/ 
IGNAR2, leading to JAK/Tyk2 activation and phosphorylation. Subsequently, STAT-1 and 
STAT2 become phosphorylated, are translocated into the nucleus, bind to the IFN- -
stimulated response element (ISRE) and the IRF7 binding sequence in target genes, such as 


























1.2.3 Other signalling pathways control downstream pro-inflammatory cytokine 
production 
    The pro-inflammatory cytokines, such as IL-1, IL-6, IL-8 and TNF-, are 
important cytokines that induce inflammatory responses and trigger the immune 
response. As previously mentioned, TNF- production is not only induced by TLRs 
but also by other signalling proteins, including members of the MAPK and C/EBP 
families. 
 
1.2.3.1 Biological functions of the MAPK pathway 
    The MAPK family consists of both stress-activated and mitogen-activated protein 
kinases. The MAPK pathway mediates signal transduction from cell surface 
receptors to downstream transcription factors, leading to cellular responses such as 
cell proliferation, growth, motility, survival and apoptosis (Robinson and Cobb, 
1997). These kinases are activated by conserved upstream protein kinase signalling 
modules, MEKs, which activate MAPK by dual-site phosphorylation on threonine 
and tyrosine residues within a Thr-X-Tyr motif located in protein kinase subdomain 
VIII (Widmann et al., 1999). 
				The classical MAPK cascade is activated by mitogens and growth factors or by 
cytokines that control cell growth and differentiation (Robinson and Cobb, 1997; 
Seger and Krebs, 1995). There are three major classes of MAPKs. The first is the 
extracellular signal-regulated kinases (ERK1/2) that acts through the Ras–Raf–
MAPK kinase pathway to regulate meiosis, mitosis and post-mitotic modification in 
differentiated cells (Seger and Krebs, 1995). Ras–GTP activates the Raf serine/ 
threonine kinase, which in turn phosphorylates and activates the MEK1 and MEK2 
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dual-specificity kinases via a series of intermediate kinases. MEKs 1 and 2 then 
phosphorylate ERK1 and ERK2, which are then translocated to the nucleus where 
they regulate the activity of various transcription factors, including cyclin D1, jun, 
fos and myc. Cyclin D1 is important in cell cycle progression, and jun, fos and myc 
are proto-oncogenes (Roberts and Der, 2007). ERKs are predominantly activated by 
growth factors or phorbol esters but can also be induced by TNF- and IL-1 (Gortz 
et al., 2005; Roberts and Der, 2007). Once activated, ERKs phosphorylate a number 
of cellular substrates that can trigger diverse signalling cascades, and accumulating 
evidence suggests an important role for ERKs in the regulation of inducible nitric 
oxide synthase (iNOS) generation in macrophages via NF-B dependent pathways 
(Jaramillo et al., 2004). Moreover, the ERK1/2 pathway regulates Bcl2 family 
proteins to promote cell survival (Balmanno and Cook, 2008). 
    The c-jun N-terminal kinases (JNK1, JNK2 and JNK3) are important for 
controlling programmed cell death (Tournier et al., 2000). The JNK signalling 
cascade is activated by stress, bacterial infection and pro-inflammatory cytokines, 
and results in phosphorylation of AP1 transcription factors (Seger and Krebs, 1995). 
JNK is involved in infection-related inflammation and septic shock, which suggests 
that JNK activation may prevent acute inflammation (Kaminska, 2005). The last 
major MAPK class is the p38 kinases (), which are activated by various pro-
inflammatory and stress stimuli, similar to JNK activation (Lee et al., 1994). In 
addition, p38 is a well-studied participant in inflammatory responses, mediating 
inflammatory cytokines, such as IL-1, IL-6, IL-8 and TNF-, that lead to immune 
responses involved in both inflammation and cancer development (Lee et al., 1994; 
Yong et al., 2009). Therefore, p38 may be a suitable therapeutic target for controlling 
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these disease processes (Yong et al., 2009). 
 
Table 1.2. Summary of the MAPK members 
Family member ERK JNK P38 




42/44 48–52 41 
Isoforms ERK1/ERK2 JNK1–3 
Location Cytosolic, nuclear Cytosolic, nuclear Cytosolic, nuclear 
Upstream 
activators 
MEK1, MEK2 MKK4, MKK7 MKK3, MKK6 












This table was modified from the Sigma-Aldrich–RBI handbook. 
 
1.2.3.2 The importance of the CCAAT enhancer-binding protein pathway 
Regulation of the C/EBP by IFN-and TLRs 
    C/EBPs belong to a large family of bZIP transcription factors (Akira and 
Kishimoto, 1997). In mammalian systems, C/EBP members participate in a number 
of physiological activities, including fat storage, tissue differentiation, growth, 
proliferation, apoptosis, immune responses and anti-bacterial defence (Anastasov et 
al., 2010; Darlington et al., 1998; Gade et al., 2008; Poli, 1998; Pradervand et al., 
2006; Zahnow et al., 2001). 
    The C/EBP subfamily includes the structurally similar but genetically and 
functionally distinct proteins, C/EBP-, C/EBP-, C/EBP-γ, C/EBP-, C/EBP- and 
C/EBP-. Deficiency in C/EBP- is linked to the pathogenesis of acute myeloid 
leukaemia (AML) (Pabst and Mueller, 2007). Although the mechanism through 
which C/EBP- causes AML is unknown, it is thought that hypo- or hyper-
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expression of CEBP- can lead to the development of different types of cancer 
(Pabst and Mueller, 2007). C/EBP- (also known as nuclear factor induced by IL-6; 
NF-IL-6) has a wider range of transcriptional targets than other C/EBP family 
members, including LAP1 (liver activating protein-1), LAP2 (liver activating 
protein-2) and LIP (liver inhibitory protein). The LAPs are transcriptional activators, 
while LIP may act as an inhibitor of C/EBPβ transcriptional activity (Calkhoven et 
al., 2000). C/EBP- regulates IL-6 function and the expression of IL-6-induced 
cytokines such as IL-1, IL-8, TNF- and granulocyte colony-stimulating factor 
(Akira and Kishimoto, 1997; Li et al., 2007), and is induced by IFN- in different 
tissues, including the spleen, liver, heart and thymus (Roy et al., 2000). Moreover, 
IFN- enhances the expression of C/EBP through MEK/ERK stimulation 
(Bonjardim et al., 2009; Hu et al., 2001; Li et al., 2007). Activated C/EBP is 
thought to require IFN- stimulation to induce STAT1-dependent ERK1/2 
phosphorylation (Hu et al., 2001). The ERK1/2 phosphorylation site on human LAP 
has been identified as Thr235 (Anastasov et al., 2010; Pilipuk et al., 2003). 
Furthermore, the induction of MyD88 signalling by TLR2 and TLR4 activates not 
only NF-B but also C/EBP and C/EBP (Lu et al., 2009). 
    In macrophage biology, C/EBP signalling is essential for oncogenic 
transformation following insulin-like growth factor I stimulation (Wessells et al., 
2004). In addition, C/EBP knockdown in macrophages is thought to decrease their 
proliferation and survival (Wessells et al., 2004). In contrast, C/EBP overexpression 
leads to macrophage hyperproliferation and increased cell size (Sebastian and 
Johnson, 2006). In macrophages of C/EBP-deficient mice infected with Listeria 
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monocytogenes and Salmonella typhimurium, these pathogens escape from the 
phagosome to the cytoplasm (Li et al., 2007). Although C/EBP has been well 
studied, the relative contribution of different isoforms to C/EBP biological function 
remains unclear (Zahnow, 2009). 
 
1.3 The potential roles of Tribbles in dog and Drosophila 
    The original name of Tribbles (Trib) was C5FW, and it was originally identified as 
one of the genes up-regulated in the thyroid of dogs in response to mitogens (Wilkin 
et al., 1996). Later, the function of the Drosophila homologue was discovered and 
the gene was renamed Tribbles (Grosshans and Wieschaus, 2000; Johnston, 2000; 
Mata et al., 2000). Trib is a regulator of Drosophila development (Grosshans and 
Wieschaus, 2000). Moreover, Trib overexpression causes G2/M arrest, indicating that 
the Trib gene is a cell cycle regulator (Mata et al., 2000; Seher and Leptin, 2000). 
Additionally, Trib protein localisation to the nucleus and the cytoplasm may be cell 
cycle-dependent (Mata et al., 2000). 
 
1.4 The major functions of Trib 
    Trib encodes a predicted 483 amino acid protein containing a central domain with 
extensive similarity to serine/threonine kinase domains VIII and IX (Mata et al., 
2000) (Seher and Leptin, 2000). However, sequence analysis of other regions of the 
Trib protein has not provided clues to its function. The function of the Trib kinase-
like domain was classified by Bowers et al. (2003). Although Trib contains a putative 
kinase-like domain, a typical core ATP-binding site or protein–protein interaction 
domain is absent. Therefore, Trib protein is classified as a pseudokinase (Hegedus et 
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al., 2007). Recent evidence has identified functions for the C-terminus (Qi et al., 
2006; Yokoyama et al., 2010), which contains two important motifs: a MEK1 
binding motif and a constitutive photomorphogenesis-1 (COP-1) binding site (Fig. 
1.7). 
 
Figure 1.7. Trib protein structure. Trib contains three unique motifs: a central pseudokinase 
domain and C-terminal MEK1-binding and COP-1-binding sites (adapted from Yokoyama et 
al., 2011). 
     
    There are three Trib gene family members in mammals, namely Trib1, Trib2 and 
Trib3 (Hegedus et al., 2006). The amino acid sequences between human Trib 
sequences are: Trib1/Trib2, 71.3%; Trib1/Trib3, 53.3%; and Trib2/Trib3, 53.7% 
(Yokoyama and Nakamura, 2011). Furthermore, the amino acid sequences of Trib are 
highly conserved between human and mouse (Trib1, 97.5%; Trib2, 99.2%; Trib3, 
81.2%) (Yokoyama and Nakamura, 2011). Trib1 and Trib3 are thought to be nuclear 
proteins, whereas Trib2 localises to the cytoplasm (Hegedus et al., 2007). 
    Trib proteins function as adaptors or scaffolds in many signalling pathways 
(Hegedus et al., 2006), and have been implicated in regulating the activity of MAPK, 
NF-B and C/EBP in inflammation and cancer, as well as in glucose, lipid and 
insulin metabolism (Du et al., 2003; Iynedjian, 2005; Qi et al., 2006). For instance, 
human Trib proteins associate with several MAP kinase kinases (MAPKK) to 
modulate MAPK signalling (Kiss-Toth et al., 2004; Yokoyama et al., 2010) (Fig. 1.8). 
Mouse Trib2 and Trib3 have been reported to be Akt-binding proteins that inhibit Akt 







activation in hepatocytes and adipocytes (Du et al., 2003; Naiki et al., 2007). 
Deficiency in C/EBP expression is reported to be strongly linked to AML 
development (section 1.2.3.2) (Pabst and Mueller, 2007), albeit through an undefined 
mechanism. Interestingly, a conserved C-terminal-binding site for E3 ubiquitin 
ligases in Trib proteins facilitates the degradation of Trib targets such as C/EBP in 
several biological systems (Keeshan et al., 2010; Keeshan et al., 2006; Mata et al., 
2000; Qi et al., 2006; Rorth et al., 2000) (Fig. 1.9). Therefore, it is suggested that 
Trib-mediated C/EBP degradation may be one of the possible mechanisms which 
contributes to AML pathogenesis (Dedhia et al., 2010; Pabst and Mueller, 2007) . 
    The regulation of cell signalling in response to stimulation is known to be cell type 
dependent (Sung et al., 2006). Therefore, Trib proteins may be multifunctional and 
their major functions have yet to be determined. 
 
                              
Figure 1.8. MAPK activation is modulated by Trib expressions. This figure indicates the 
proposed level at which Trib interacts with the MAPK cascade. The downstream biological 
effects on proliferation, differentiation and apoptosis are mediated by Trib–ERK, Trib–JNK 













                            
Figure 1.9. Trib interacts with COP1 and regulates C/EBP. Trib recruitment of COP1 to the 
COP1-binding site is required for C/EBP ubiquitination. Following C/EBP ubiquitination, 
proteasome-mediated degradation and post-transcriptional suppression of C/EBP initiates 
biological processes, such as myeloid differentiation (adapted from Keeshan et al., 2010; and 
Yokoyama et al., 2011). 
 
 
1.4.1 Mammalian Trib1 
    Human Trib1 was first identified as a Trib2 homologue based on a partial cDNA 
sequence (Wilkin et al., 1997). Alternative names for Trib1 include C8FW (Wilkin et 
al., 1997) and SKIP (Bowers et al., 2003). Trib1 is associated with both innate and 
adaptive immunity, inflammation and leukocyte differentiation. Moreover, Trib1 
protein interacts with the MAPK and C/EBPs pathways to modulate downstream 
responses, including inflammation. 
    Trib1 was first evaluated as a regulator of the Toll/IL-1 receptor in innate immune 













Toth et al., 2004; 2005). Trib1-deficient mice were generated by Yamamoto et al. 
(2007), and macrophages from these mice demonstrated that loss of Trib1 up-
regulates inflammatory mediators, including prostaglandin E synthase, arginase II 
and plasminogen activator inhibitor type II. LPS-stimulated C/EBP expression was 
also inhibited in Trib1-deficient macrophages. In the nematode (Caenorhabditis 
elegans) system, a kinase identified by Pujol’s group that resembles human Trib1 
protects against fungal infection, possibly by activating MAPK signalling upstream 
of MAPKK (Pujol et al., 2008). Together with Kiss-Toth’s work, which found that 
Trib1 regulates the MAPK pathway in HeLa cells (Kiss-Toth et al., 2004), these 
studies indicate that Trib1 is associated with the innate immune response against 
infection. 
    Trib1 expression was also detected in human CD4+ CD25+ regulatory T (Treg)-
cells by microarray analysis (Pfoertner et al., 2006). Trib1 is also expressed in 
activated APCs and in endothelial cells (Ashton-Chess et al., 2008), where it may 
play a role in activating the adaptive immune response. Therefore, Trib1 plays a role 
in both innate and adaptive immunity. 
    Human Trib1 has been reported to control the proliferation of vascular smooth 
muscle cells and chemotaxis via inhibition of the MAPK–JNK pathway (Sung et al., 
2007). In addition, Trib1 expression is increased in human atherosclerotic arteries 
relative to non-atherosclerotic controls, implying that Trib1 may be associated with 
atherosclerosis disease in vivo. Recently, Trib1 was reported to control white adipose 
tissue (WAT) inflammation by direct regulation of the NF-B pathway in pro-
inflammatory signalling (Ostertag et al., 2010). This study confirms that Trib1 has a 




    There is a strong correlation between Trib1 and myeloid leukaemia. Trib1 is a 
novel myeloid oncogene that enhances ERK phosphorylation, resulting in the 
inhibition of apoptosis during myeloid leukaemogenesis (Jin et al., 2007). The Hox 
gene has a key role in haematopoiesis and regulates myeloid differentiation, and 
HoxA is important for myeloid leukaemogenesis, along with Meis1 (Argiropoulos 
and Humphries, 2007). Trib1 expression is up-regulated by retroviral integration in 
the mouse leukaemogenesis model and cooperates with Hox, Meis1 and Evil. 
Therefore, Trib1 is associated with the induction of AML in mice (Jin et al., 2007), 
as well as in humans. Trib1 degrades C/EBP during myeloid leukaemogenesis 
through interaction with MEK-1 (Yokoyama et al., 2010). These findings suggest 
that Trib1 both promotes C/EBP degradation and inhibits C/EBP expression. 
    Retinoic acid (RA) has an important function in development and homeostasis 
through regulating cell proliferation, differentiation and apoptosis (Mark et al., 2006). 
Trib1 is also thought to interact with nuclear receptors and may contribute to retinoic 
acid receptor signalling by inhibiting the function of RA receptors involved in the 
progression of cancers, including AML (Imajo and Nishida, 2010). 
    In addition to its pro-inflammatory role, Trib1 has been reported to function in the 
differentiation of HC11 mammary epithelial cells (Perotti et al., 2009), which are 
widely used for studying proliferation, signal transduction and differentiation 
(Chammas et al., 1994). Perotti’s group surveyed more than 15,000 genes and found 
that approximately 20% of genes to undergo differentiation and Trib1 is inclusive. 
Thus, Trib1 is involved in mammary epithelial cell differentiation (Perotti et al., 
2009).     
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    In conclusion, Trib1 is involved in many biological processes, including the innate 
and adaptive immune responses, inflammation and differentiation. 
 
1.4.2 Mammalian Trib2 
    Trib2 was first identified by Wilkin et al. (1996) as a phosphoprotein expressed in 
dog thyroid cells. Trib2 mainly contributes to the regulation of haematopoietic 
diseases, such as AML, as well as chronic inflammatory diseases, such as 
atherosclerosis. 
    Bisoffi et al. (2004) showed that Trib2 was markedly up-regulated in androgen-
independent bone metastatic prostate cancer cells compared with their non-metastatic 
counterparts. This data indicates that Trib2 may play a role in tumour metastasis. 
Similar to Trib1, Trib2 cooperates with HoxA9 to induce AML by inactivating 
C/EBP (Keeshan et al., 2006; Keeshan et al., 2008). Accumulated evidence 
indicates that Trib1 and Trib2 have potential roles in inducing AML via C/EBP 
inactivation (Dedhia et al., 2010). Moreover, sequence analysis reveals that the C-
terminal region of Trib2 also contains a COP-1 binding site. COP-1 recruitment is 
essential for Trib2-induced AML; in the absence of COP-1 binding, C/EBP 
function is normal and AML doesn’t develop (Keeshan et al., 2010). In addition, 
Trib2/ C/EBP may contribute to human lung cancer through another E3 ligase, 
TRIM21 (Grandinetti et al., 2011). Further, Trib2 is reported to be pro-apoptotic in 
haematopoietic precursor cells (Lin et al., 2007). The Trib2 transcript is down-
regulated following treatment of Notch-dependent T cell acute lymphoblastic 
leukaemia cells with -secretase inhibitors, and is Trib is therefore assumed to be a 
Notch target (Wouters et al., 2007). 
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    Trib2 has been reported to bind Akt and inhibit Akt activation during adipocyte 
differentiation (Naiki et al., 2007). Recently, Trib2 was shown to negatively regulate 
forkhead box protein O (FOXO), a downstream transcription factor of the Akt 
pathway. In addition, Trib2 supports the growth and survival of melanomas by down-
regulating FOXO activity (Zanella et al., 2010). 
    Interestingly, Trib2 was reported to inhibit MEK1 and MKK7 in macrophages and 
to modulate IL-8 production (Eder et al., 2008), thus connecting Trib2 activity to the 
immune response. In addition, Trib2 is up-regulated in macrophages within human 
atherosclerotic regions, suggesting that Trib2 is a marker of atherosclerosis 
progression (Deng et al., 2009). 
    Thus, the main functions of Trib2 are to down-regulate C/EBP, Akt and     
MAPK for modulating the progression of haematopoietic diseases, cancers and 
atherosclerosis. 
 
1.4.3 Mammalian Trib3 
    Trib3 is a well-studied member of the mammalian Trib family (Hegedus et al., 
2006) associated with a broad range of biological activities, such as nutrient 
metabolism, and diseases, including cancers and atherosclerosis. Trib3 plays a role in 
these processes through regulating signalling pathways, such as Akt and MAPK. 
    In 1999, Mayumi’s group identified Trib3 as a factor induced in neuron cell death 
(Mayumi-Matsuda et al., 1999). Trib3 is highly expressed in human liver, with lower 
levels of expression in haematopoietic compartments such as the bone marrow, 




    Trib3 function is associated with several biological processes such as glucose and 
lipid metabolism (Du et al., 2003; Iynedjian, 2005; Koo et al., 2004; Okamoto et al., 
2007; Qi et al., 2006). Trib3 has been proposed to block insulin signalling through 
inhibition of Akt phosphorylation in the liver (Du et al., 2003). However, another 
study found that Trib3 overexpression does not reduce insulin-induced Akt 
phosphorylation in the liver (Iynedjian, 2005). Interestingly, Okamoto and his 
colleagues reported that Trib3 knockout mice have normal insulin signalling and 
glucose homeostasis in the liver (Okamoto et al., 2007). Therefore, the role of Trib3 
in nutrient metabolism remains controversial. 
    Trib3 negatively regulates a variety of signal transducers through different 
mechanisms. For instance, Trib3 interacts with the activation transcription factor 4 
(ATF4) receptor (Ord D and Ord, 2003) to block Akt phosphorylation (Du et al., 
2003). Corcoran and his colleagues (Corcoran et al., 2005) showed that cellular 
stress can up- or down-regulate Trib3 expression through the p65 NF-B signalling 
pathway. Further, Trib3 stimulates the degradation of acetyl CoA carboxylase (ACC), 
an important enzyme in fatty acid synthesis, by recruiting the E3 ubiquitin ligase, 
COP1 (Qi et al., 2006). Trib3 is also reported to interact with MEK1 and MKK7, the 
upstream components of the MAPK pathway (Kiss-Toth et al., 2004), that the 
consequences of this interaction are unknown 
    Similar to Trib1 and Trib2, Trib3 is associated with the development of 
atherosclerosis (see sections 1.4.1 and 1.4.2; (Deng et al., 2009; Shang et al., 2009; 
Sung et al., 2007). Trib3 is also involved in caspase 3-mediated macrophage 
apoptosis, and is induced by oxidised low-density lipoprotein (ox-LDL). Moreover, it 
plays an essential role in the progression of vulnerable atherosclerotic plaques. 
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Consequently, Trib3 mediates macrophage apoptosis induced by ox-LDL and is also 
associated with inflammation (Shang et al., 2009). 
    In summary, Trib1 is involved in immunity, inflammation and differentiation, and 
is associated with haematopoietic diseases and chronic inflammation. Trib3 plays 
roles in nutrient starvation and cancer development, as well as in chronic 
inflammation. A summary of the major signalling pathways involving Trib family 
members is shown in Table1.3. 
 
Table 1.3. Summary of Trib functional roles in different signalling pathways 
Pathway Trib1 Trib2 Trib3 
MAPK Interaction with 
MEK1/MKK4 
(Kiss-Toth et al., 2004) 
Inhibition of 
MEK1/MKK7 (Eder 
et al., 2008) 
Interaction with 
MEK1/MKK7 (Kiss-
Toth et al., 2004) 
Akt Unknown Negative regulator 
(Naiki et al., 2007) 
Negative regulator 
(Du et al., 2003) 
C/EBP Inhibition through 
MEK1 in AML (Dedhia 
et al., 2010; Yokoyama 
et al., 2010) 
Inhibition through 
COP-1 in AML 
(Keeshan et al., 
2010) 
Failed to degrade 
C/EBP in AML 
(Dedhia et al., 2010) 
C/EBP Inhibition 
(Yamamoto et al., 2007) 
Unknown Unclear 
Notch Unknown Downstream target 







1.5 Aims of this PhD project 
    From previous studies, it is clear that Trib family members are associated with 
inflammatory processes and disease, including atherosclerosis (Trib1/2/3). Trib1 is 
involved in LPS stimulation of murine bone marrow derived macrophages through 
C/EBP. Trib family members modulate many signalling pathways, such as the 
MAPK pathway, and C/EBPs during inflammation and cancer development. 
However, some findings are contradictory in different mammalian systems. 
Moreover, no direct evidence links Trib family members to TLRs, cytokine-induced 
inflammation or stimulation of the innate immune system. 
    Therefore, the aims of this study are to investigate the biological functions of Trib 
family members and to determine whether they contribute to innate immunity, for 
example through regulating macrophage function, within in vitro systems. Previous 
reports have not defined how Trib family members activate the innate immune 
system. Specifically, it remains unclear how Trib family members contribute to 
macrophage activation or inactivation following stimulation with TLRs and pro- and 
anti-inflammatory cytokines. Trib functions were previously examined in Drosophila; 
however, these remain controversial in mammalian systems. 
 
Hypothesis 
    My overall hypothesis is that Trib family members play a modulatory role during 






Specifically, the thesis aims are: 
1. to identify which Trib family members are expressed under inflammatory 
conditions in a myeloid cell line (RAW264.7) and to determine the level and 
pattern of Trib expression; 
2. to identify novel targets of Trib-associated signalling in macrophages; 
3. to establish a Trib loss-of-function system using short interfering RNA (siRNA) 
targeting techniques in order to understand the physiological and biological 




Chapter 2: Materials and methods 
2.1 In vitro experimental design 
2.1.1 Cell culture 
    Passage 6 murine monocyte/macrophage RAW264.7 cells, generated from 
BALB/c mice (ATCC number TIB-71), were kindly provided by Professor Tony 
Nash (Royal Dick School of Veterinary Studies, University of Edinburgh). 
RAW264.7 cells were cultured in Dulbecco’s modified essential medium (DMEM) 
(GIBCO, Paisley, UK) supplemented with 10 % (v/v) FCS, 100 µg/ml streptomycin 
and 100 U/ml penicillin (GIBCO, Paisley, UK) in a humidified incubator at 37°C 
with 5% CO2. 
    To passage cells, medium was removed by pipetting, and cells were washed twice 
in 10 ml PBS (phosphate-buffered saline). Cells were detached by a cell scraper (240 
mm, Helena Bioscience, UK) that according to ATCC instructions. Cells were split as 
required (1:20) and seeded directly into new culture vessels with fresh medium. 
2.1.2 Cell stimulation 
    Cell numbers were adjusted to 2×105 cells/well incubated overnight. Culture 
medium (0.5 ml) was removed from each well and replaced with 0.5 ml fresh 
medium containing cytokines (recombinant mouse IFN- and IL-10, both purchased 
from eBioscience, UK) and/or TLR ligands (TLR1/2 stimulation, Pam3CSK4 was 
referred to TLR2 ligand in the thesis, and TLR9 ligand, ODN1826 CpG DNA; 
InvivoGen, San Diego, USA) to the final concentrations shown in Table 2.1. Cells 
were harvested 0 hr, 0.5 hr, 1 hr, 3 hr, 6 hr, 8 hr and 24 hr post-stimulation for RNA 
extraction. Culture supernatants from 24 hr and 48 hr time points were stored at 
˗20°C for ELISA analysis. 
39 
 
Table 2.1. Concentrations of the immune modulators used in this study.  
Immune modulator Low concentration High concentration 
untreated - - 
IL-10 1.0 ng/ml 10 ng/ml 
IFN-  0.1 ng/ml 1.0 ng/ml 
TLR9 ligands 
(ODN1826 CpG DNA) 
1 nM 100 nM 
IL-10+TLR9L TLR9L(1 nM) IL-10 (10 ng/ml) 
IFN- TLR9L TLR9L (1 nM) IFN- (1.0 ng/ml) 
TLR2 ligands (Pam3CSK4) 1 ng/ml 50 ng/ml 
IL-10+TLR2L TLR2L (1 ng/ml) IL-10 (10 ng/ml) 
IFN- TLR2L TLR2L (1 ng/ml) IFN- (1.0 ng/ml) 
 
2.1.3 Cell storage in liquid nitrogen 
    RAW264.7 cells were grown to near confluency and frozen at a concentration of 
approximately 5×106 cells in 0.5 ml freezing medium (Appendix B). The cell 
suspension was centrifuged at 200×g for 5 min, resuspended in an appropriate 
volume of freezing medium, aliquoted into cryovials, transferred to an isopropanol 
chamber and placed at ˗80°C. Using an isopropanol freezing vessel provides a steady 
freezing rate of 1°C/min, which ensures the successful cryopreservation of cells and 
reduces cell death. After at least 3 hr, cryovials were transferred to liquid nitrogen for 
long-term storage. 
 
2.2 Molecular techniques 
2.2.1 Total RNA extraction 
    Total RNA was extracted from RAW264.7 cells using an RNeasy Mini Kit 
(Qiagen, Crawley, UK, 74104) according to the manufacturer’s instructions. Culture 
medium was removed and cells were washed in PBS. RLT buffer (350 µl) containing 
3.5 µl β-mercaptoethanol (β-ME) was added to the cells, lysates were obtained by 
pipetting and transferred to a QIAshredder (Qiagen, Crawley, UK, 79654) spin 
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column, followed by centrifugation at 8,000× g (Eppendorf, MiniSpinPlus) for 2 
min. An equal volume of 70% (v/v) ethanol was added to the lysate, mixed by 
pipetting. The mixture was transferred to an RNeasy spin column and centrifuged for 
15 s at 8,000×g. Buffer RW1 (700 µl) was added to the column, and the column was 
centrifuged for 15 s, washed twice with 500 µl RPE/ethanol buffer, and 
centrifugation for another 1 min. Finally, 30 µl nuclease-free water was added to 
elute the RNA. 
2.2.2 DNA removal 
    To ensure no DNA contaminated the RNA samples, 3 µl of 10× TURBO DNase 
buffer and 1.5 µl TURBO DNase (TURBO DNA-free kit, AppliedBiosystems 
AM1907, Foster City, CA, USA) were added to the eluted RNA, mixed gently and 
incubated at 37°C for 30 min. DNase Inactivation Reagent (typically one-tenth 
volume) was added, mixed well and incubated for 5 min at room temperature. Tubes 
were centrifuged at 10,000×g (Eppendorf, Centrifuge 5415R) for 1.5 min and RNA 
was transferred to a new tube. RNA concentration was measured using a NanoDrop 
ND1000 (Thermo Fisher Scientific, Leicestershire, UK) according to the 
manufacturer’s manual at absorbances of 230 nm, 260 nm and 280 nm (A230, A260, 
and A280, respectively). RNA purity of was determined by calculating the A260/A280 
ratio. Only good quality RNA with a ratio of 1.9–2.1 was used for experiments. 
2.2.3 cDNA synthesis 
    All DNA oligonucleotides were purchased from Eurofins MWG Operon 
(eurofinsdna.com). Primers were designed using the Primer 3 programme 




2.2.3.1 Reverse transcription 
    cDNA was synthesised from RNA using a Reverse Transcription System 
(Promega, Hampshire, UK). RNA (0.4 µg) was added to a master mix solution 
containing 4 µl of 25 mM MgCl2, 2 µl of 10× reverse transcription buffer, 2 µl of 10 
mM dNTP mixture, 0.5 µl RNasin ribonuclease inhibitor, 15U of avian 
myeloblastoma virus reverse transcriptase (AMV-RT) and 2.5 µl random hexamers 
adjusted to a final volume of 20 µl with RNase-free water. Samples were incubated 
for 10 min at room temperature, then at 42°C for 1 hr to synthesise cDNA, before 
heating to 95°C for 5 min and then incubating at 0°C for 10 min to inactivate the 
AMV-RT. cDNA samples were stored at ˗20°C. 
2.2.3.2 DNA amplification by the polymerase chain reaction (PCR) 
    cDNA samples were used as templates to amplify Tribs 1–3 and GAPDH. PCR 
reactions comprised 100 pmol forward primer, 100 pmol reverse primer, 2 µl of 10× 
PCR master mix buffer, 0.5 µl BIOTAQ Red DNA polymerase (Bioline, UK) and     
2 µl cDNA, adjusted to a final volume of 20 µl with RNase-free water. PCR cycling 
conditions were 1 cycle of 94°C for 2 min; 30 cycles of 94°C for 1 min, 55°C for 1 
min, 72°C for 1 min; and a final step of 72°C for 10 min. PTC-100 hot lid thermal 
cyclers were used (MJ Research Inc., Watertown, Mass, USA ). To assess the 
consistency of sample loading and PCR conditions between individual experiments, 
cDNA amplification of the abundantly expressed housekeeping gene glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) was included as the internal control. Primer 






Table 2.2. List of primers used in this study 




Murine Trib1 forward ACTAATTGCTTTGGGAAGTG
294 
Murine Trib1reverse TTTGCAGATAGAGCTTGGAT
Murine Trib2 forward GGAAAAACATTTTGCCACTC
221 
Murine Trib2 reverse TCTGTCCCAATACGCACCTT
Murine Trib3 forward GGCTGTTTCTTCCTCCAGAA
246 
Murine Trib3 reverse CCCTGGTTGAGAGAGGATCA
Murine GAPDH forward AACTTTGGCATTGTGGAAGG
472 
Murine GAPDH reverse CCCTGTTGCTGTAGCCGTAT
 
2.2.3.3 Agarose gel electrophoresis 
    Agarose (2.0% (w/v); Bioline, London, UK) gels made with 1× TAE buffer 
(Appendix B) were used for the standard analysis of DNA fragments by 
electrophoresis (Flowgen, Ashby de la Zouch, UK). 
    Samples of PCR products were loaded and run on gels in 1× TAE buffer at 100 V 
for 60 min, stained with Biotium GelRed (Cambridge Bioscience, Cambridge, UK) 
and DNA bands were visualised using the Bio-Rad gel documentation system (Bio-
Rad Molecular Imager FX, Hercules, CA). DNA ladder (1µg of 1kb plus, Invitrogen, 
Renfrew, UK) was used as a size marker. Kodak Digital Science 1D Image Analysis 
software (PerkinElmer) was used for measuring DNA band intensities. 
2.2.3.4 Purification of PCR products 
    PCR products were purified for sequencing using the Wizard PCR Preps DNA 
Purification System (Promega, Hampshire, UK). PCR products (100 µl) were mixed 
with 1 ml DNA–binding resin and vortexed vigorously three times for 1 min. The 
DNA–resin mixture was added to a Wizard PCR Preps DNA Purification System 
mini column, the resin was washed with 2 ml of 80% (v/v) isopropanol, and then    
40 µl nuclease-free water was used to elute purified DNA from the resin. 
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2.2.3.5 DNA sequencing 
    In order to confirm primer specificity and that no mutations had been introduced 
during DNA amplification, DNA samples were sequenced by DBS Genomics at 
Durham University, UK, using an Applied-Biosystems 3730 DNA Analyser 
(AppliedBiosystems, Warrington, UK). Sequencing samples (5 µl PCR products 
diluted in nuclease-free water, together with 1 µl primer) were sequenced in both 
directions using the BigDye Terminator v3.1 (Applied Biosystems, UK) sequencing 
reaction, followed by capillary analysis using an ABI3730 DNA analyser 
(AppliedBiosystems, UK). 
2.2.4 Quantification of gene expression using real-time PCR 
    All real-time PCR reactions were performed on a Roche LightCycler 480 
Instrument using LightCycler 480 Multiwell Plate 96 following the manufacturer’s 
recommendations. To compare relative mRNA levels in treated and control samples, 
duplicate samples were analysed as three technical replicates. Two negative controls 
were included in all assays; a ‘no template’ control (in which the cDNA template was 
replaced with nuclease-free water) and an RNA control (in which reverse 
transcriptase has been omitted from the cDNA synthesis reaction, and which checks 
for genomic DNA contamination of RNA samples). 
2.2.4.1 Reverse transcription 
    cDNA synthesis was performed using the Transcriptor High Fidelity cDNA 
Synthesis Kit (Roche, West Sussex, UK). Total RNA (0.4 µg) and 2 µl of random 
hexamer primers were mixed and the volume was made up to 11.4 µl with nuclease-
free water. PCR tubes were placed in the thermocycler (iCycler, Bio-Rad, Hemel 
Hempstead, UK) and incubated at 65°C for 10 min to allow primer annealing. This 
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reaction was then added to a solution containing 20 U of Protector RNase Inhibitor, 
1 mM of each dNTP, 5 mM of DTT and 10 U of rRT in manufacturer’s buffer was 
aliquoted into the template-primer mixes and incubated at 50°C for 30 minutes. The 
enzyme was inactivated by an incubation step at 85°C for 5 minutes. Nuclease-free 
water (80 µl) was added and the single-stranded cDNA was stored at ˗20°C. 
2.2.4.2 Quantitative real-time PCR (qPCR) 
    qPCR reactions were performed using a LightCycler 480 Real-Time PCR System 
(Roche, West Sussex, UK) according to the manufacturer’s protocol. Diluted cDNA 
samples (5 µl) were added to a PCR mixture containing 10 µl of 2× Universal PCR 
Master Mix (Roche), 1 pair of primers (FP and RP) containing 1µl FAM-probe and a 
second pair of primers containing 1 µl VIC-probe, and made up to 20 µl final volume 
with nuclease-free water. Trib 1–3 primers and probes were obtained from ABI 
(Trib1 Mm00454875_m1, Trib2 Mm00454876_m1 and Trib3 Mm00454879_m1, 
AppliedBiosystems, Warrington, UK). Negative controls contained water or RNA 
samples, as described above. qPCR reaction steps were: pre-incubation at 95°C for 
10 min; 45 cycles of denaturation at 95°C for 10 s, annealing at 60°C for 30 s, 
extension at 72°C for 1 s; cooling at 40°C for 10 s. Each sample was normalised to 
mGAPDH expression (Mm03302249_g1). 
2.2.4.3 Relative gene expression analysis 
    Relative gene expression analysis was performed using the comparative delta–
delta method (Pfaffl, 2001). 
    The analyses of real-time PCR described in Chapter 3 were performed under 
different conditions from those in Chapters 4 and 5. For the experiments described in 
Chapter 3, the reference gene and target gene primers were added to the same well 
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(multiplexing Trib1 and mGAPDH). The delta Ct value (dCt = mean Ct of target 
gene − mean Ct of reference gene) was calculated for each sample, and the time zero 
control samples (t0) were then averaged and the time zero control dCt0 value was 
calculated. The delta–delta Ct value (ddCt) represents the difference between the dCt 
value for the treated (untreated) sample and the time zero control sample. The 
relative expression of the target gene was then calculated from the formula shown 
below. 
    Relative expression (RE) = 2-ddCt 
    The 2-ddCt equation was used to measure the expression efficiency of target genes. 
    In Chapters 4 and 5, real-time PCR reactions were performed in duplicate on 
transfected samples and untransfected controls, and the reference gene and target 
gene primers were added to the same well (multiplexing Trib1 and mGAPDH). The 
delta Ct value (dCt = mean Ct target gene − mean Ct reference gene) was calculated 
for each sample, and the untransfected controls were averaged to produce the 
untransfected control dCtunt value. The delta–delta Ct value (ddCt) was the defined as 
the difference between the dCt values for transfected cells and untransfected controls. 
The relative expression level of the target gene was then calculated using the formula 
shown above. 
2.2.5 Bacterial transformation 
    The pCMV-Trib1 expression plasmid was purchased from Source BioScience 
(Nottingham, UK). An AmpR gene was incorporated into the pCMV-Trib1 vector to 
allow the selection of transformed colonies by antibiotic-resistant. The Trib1 insert 
size was 2,600 bp approximately when it was cut by the two restriction enzymes; 
SalI (5ʹ ) and NotI (3ʹ ).  
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    Plasmid DNA (500 ng) was added to 200 µl competent Escherichia coli DH5 
cells (Invitrogen, Paisley, UK). DNA and incubated on ice for 30 min. Next, the 
DNA and bacteria mixture was heat-shocked at 42°C for 1 min and then cooled on 
ice for 2 min. Super Optimal broth and Catabolite repression medium (SOC) (1 ml; 
2% Bacto-tryptone, 0.5% Bacto-yeast extract, 8.5 mM NaCl, 2.5 mM KCl and 20 
mM glucose, pH7.0) was added and incubated at 37°C, with shaking at 250 rpm for 1 
hr. Transformants were plated onto LB agar containing 50 µg/ml ampicillin. 
2.2.6 Preparation of plasmid DNA 
2.2.6.1 Mini preps.  
    Individual E. coli DH5 transformed colonies were picked and propagated 
overnight in 5 ml Luria-Bertani (Appendix B) medium containing 50 µg/ml 
ampicillin at 37°C with shaking at 250 rpm. Plasmid DNA was recovered using a 
Pure Yield Plasmid MiniPrep System (Promega, Hampshire, UK). Bacterial culture 
(3 ml) was pelleted by centrifugation at 10,000×g for 5 min and the supernatant was 
removed. Pelleted cells (200 µl) were mixed with 200 µl cell lysis solution, and then 
200 µl cell neutralisation solution was added and mixed, and the mixture was 
centrifuged to remove cell debris. The clarified supernatant was added to 1ml DNA-
binding resin and applied to a mini column. Endotoxin removal wash (200 µl) was 
added to the mini column and it was centrifuged at maximum speed for 15 s. Column 
wash solution (2 ml) was then added to the mini column and removed by 
centrifugation. Nuclease-free water (50 µl) was added to the column and centrifuged 






2.2.6.2 Maxi preps.  
 
    A single transformed bacterial colony was inoculated into 3 ml LB containing 50 
µg/ml ampicillin and incubated for 6 hr at 37°C with shaking to produce a starter 
culture. The starter culture was diluted 1:500 into 150 ml LB containing 50 µg/ml 
ampicillin and incubated overnight at 37°C with shaking at 250 rpm. Large-scale 
plasmid DNA extraction was carried out using the GenElute HP Endotoxin-Free 
Plasmid Maxiprep Kit (Sigma-Aldrich, Dorset, UK). Briefly, 150 ml bacterial culture 
was pelleted by centrifugation at 5,000×g for 10 min at 4°C, and the supernatant was 
discarded. During this time, a binding column was prepared by allowing 12 ml 
column preparation solution to flow through the column matrix. The bacterial pellet 
was resuspended in 12 ml resuspension/RNaseA solution, 12 ml lysis solution was 
added, mixed and then incubated at room temperature for 5 min. Chilled 
neutralisation solution (12 ml) was added, gently inverted to mix, and then incubated 
at room temperature for 5 min. Insoluble proteins were removed by passing through 
an endotoxin-free Maxi cartridge. Binding buffer (9 ml) was added to the filtered 
lysate and mixed, and the mixture was added to a binding column and allowed to 
pass through by gravity. The column was washed sequentially with 12 ml each of 
wash solution 1 and was solution 2 and the column was then air-dried for at least 30 
min. Nuclease-free water (5 ml) was then added to the matrix and the column was 
centrifuged at 8,000×g to elute the DNA. The concentration of plasmid DNA was 





2.3 Transient transfection of mammalian cells 
    RAW264.7 cells were transfected by electroporation. All transfection protocols 
were optimised to obtain the maximum gene knockdown while maintaining high cell 
viability and transfection efficiency. 
2.3.1 Transfection by electroporation 
    For small interfering RNA (siRNA) knockdown experiments, 2×106 RAW264.7 
cells were transfected with siRNA using the Amaxa Cell Line Nucleofector Kit V 
(cat.no. VCA-1003) and programme D-32 (Nucleofector II). Confluent RAW264.7 
cells were split at a ratio of 1:4 into new 75cm2 flasks24 hr before transfection. The 
following day, cells were harvested and washed twice with PBS. Subsequently, 
2×106 cells were resuspended in 90 µl solution V and mixed with 10 µl siRNA in a 
1.5 ml microcentrifuge tube. Cells were transfected with either a scrambled siRNA as 
a negative control or the pmaxGFP green fluorescent protein (GFP) expression 
vector (Amaxa, provided with the kit) as a positive control. After transfection, 500 µl 
warmed culture medium was added to the microcentrifuge tube and transfected cells 
were transferred into pre-warmed 6-well plates for overnight incubation. The 
transfection efficiency was analysed by counting GFP-positive cells by FACS and 
knockdown efficiency was analysed at the mRNA level by qPCR. Trib1 specific 
siRNAs and negative control Silencer Select siRNAs were purchased from Ambion, 









Table 2.3. Trib1 specific siRNA sequences used in this study 
siRNA identification 
code 
Sequences (5ʹ to 3ʹ) 
s102503 sense CGCUUUUGGUCGGACGAUAtt 
s102503 antisense UAUCGUCCGACCAAAAGCGta 
s102505 sense GAUGAUGCGCUGUCAGAUAtt 
s102505 antisense UAUCUGACAGCGCAUCAUCtt 
s202130 sense GGGCUAUGUUGACUCAGAAtt 
s202130 antisense UUCUGAGUCAACAUAGCCCgg 
 
2.3.2 Microscopic analysis 
    For experiments described in Chapter 3, the morphology of treated and control 
RAW264.7 cells were examined using a Leitz Laborlux S microscope (Leica 
Microsystems GmbH, Wetzlar, Germany) at 25× magnification. Digital images were 
captured using an Exwave HAD 3CCD video camera. 
    For experiments described in Chapters 4 and 5, the morphology of transfected 
cells was examined by inverted microscope (Axiovert 40CFL, Carl Zeiss, 
MicroImaging GmbH, Jena, Germany) after overnight incubation. Cytocentrifuge 
smears were prepared from non-adherent cells as follows. Double cytofunnel 
cuvettes (Cytospin3, Shandon, Thermo Fisher Scientific Inc., Waltham, MA, USA) 
were mounted onto Superfrost microscope slides in metal holders. Cell suspension 
(100 µl) was place into each cuvette and cuvettes centrifuged at 350 rpm for 3 min in 
a Cytospin3 centrifuge (Cytospin3, Shandon, Thermo Fisher Scientific Inc., Waltham, 
MA, USA). Slides were carefully extracted and air-dried and then cells were 
examined using an inverted microscope. Photographs were taken using an AxioCam 





2.4 Protein analysis 
2.4.1 Preparation of RAW264.7 whole cell protein extracts 
    Culture medium was removed and cells were rinsed with cold PBS containing 1× 
β-phosphatase inhibitors. Cells were detached using a scraper, transferred to 1.5 ml 
microcentrifuge tubes and washed with cold PBS. Cold NP-40 lysis buffer (20 µl; 
1% (v/v) NP-40, 150 mM KCl, 25 mM HEPES, 5 mM DTT, 50 mM NaF and 1× 
Roche Protease Inhibitor Cocktail Tablets) was added to each cell pellet. Cells were 
lysed by thorough pipetting in lysis buffer and incubated on ice for 15 min. Lysates 
were centrifuged at 10,000×g (Eppendorf, Centrifuge 5415R) for 15 min at 4°C and 
supernatants containing whole cell soluble protein extracts were stored at ˗70°C. 
2.4.2 Determination of protein concentration by the Bradford method 
    A Quick Start Bradford Protein Assay (Bio-Rad, Hemel Hempstead, UK) was 
performed according to the manufacturer’s protocol to determine the protein 
concentration of the cell lysates. Samples were diluted 1:10 and 5 µl of each protein 
standard or sample was pipetted into individual wells of a 96-well plate containing 
250 μl 1× dye reagent (Bio-Rad, Hemel Hempstead, UK). Samples were incubated 
room temperature for 10 min to allow colour development and the absorbance at 595 
nm was measured using a 1420 VICTOR3 plate reader (PerkinElmer). Protein 
concentrations were calculated by reference to a bovine serum albumin standard 
curve. 
2.4.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
    Protein electrophoresis was carried out using a Bio-Rad Mini Protean III system 
(Bio-Rad, Hemel Hempstead, UK) and standard 12% Laemmli SDS-polyacrylamide 
gels (Appendix B). The resolving gel (Appendix B) was poured first, overlaid with 
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distilled water to prevent air bubbles forming, allowed to set at room temperature and 
then the distilled water was removed. The stacking gel (Appendix B) was poured, 
ten-well combs were inserted and the gel was allowed to set at room temperature. 
    Protein samples (40–50 µg) were prepared in 2× SDS sample buffer (Appendix B) 
and boiled in a heat block for 5 min at 95°C to denature the proteins. The gel was 
immersed in running buffer (Appendix B), and samples were loaded into wells and 
subjected to electrophoresis at 150 V until the dye front had run off the bottom of the 
resolving gel. Gel plates were disassembled and the gels placed in 1× transfer buffer 
(Appendix B) for 10 min. Pre-stained Full Range Rainbow Markers (5 µl; Amersham 
Pharmacia Biotech) were included to allow size estimation of protein bands. 
2.4.4 Protein transfer to nitrocellulose membranes 
    Gels containing separated proteins were assembled in the transfer cassette with 
nitrocellulose membrane (GE healthcare, Chalfont St Giles, UK, RPN203D) and 
Whatman filter papers, according to the manufacturer’s instructions. The transfer 
cassette (Mini Trans-Blot Cell, Bio-Rad Hemel Hempstead, UK) was placed in a 
transfer tank containing 1× transfer buffer and protein transfer was performed at 100 
V for 1 hr at room temperature with an ice pack. 
2.4.5 Immunoblotting 
    Nitrocellulose membranes were rinsed with water and reversibly stained with 
0.1% (w/v) Ponceau-S solution in 5% acetic acid (Sigma-Aldrich, Dorset, UK) to 
check the efficiency of protein transfer, and then washed in TBST (Appendix B) 
buffer. Membranes were blocked with 5% (w/v in TBST) skimmed milk powder 
(OXOID, Cambridge, UK) solution for 1 hr at room temperature, and then incubated 
with the appropriate antibody dilution (in 3% (w/v) skimmed milk in TBST; see 
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Table 2.4) overnight at 4°C. The membranes were then washed three times in TBST 
for 5 min each time to remove excess antibody. Membranes were then incubated with 
horseradish peroxidase-linked (HRP) secondary antibody (diluted in 3% (w/v) 
skimmed milk in TBST; see Table 2.4) for 1 hr at room temperature, washed five 
times in TBST for 5 min each time, and protein signals were detected using the ECL 
reagent (1:1 mixture of solutions 1 and 2; Appendix B) and exposure to Lumi-Film 
chemiluminescent detection film (Amersham Biosciences). Protein sizes were 
determined by comparison with pre-stained markers. 
Table 2.4. List of the primary and secondary antibodies 
Primary antibody Host 
animal 
Source (catalogue number) Dilution 
Anti-ɑ/β tubulin Rabbit Cell Signaling (2148) 1:1000 
Anti-total ERK1/2 Mouse Cell Signaling (9272) 1:2000 
Anti-Phospho-ERK1/2 
(E10) 
Mouse Cell Signaling (9106) 1:2000 









Secondary antibodies Host 
animal
Source (Catalogue number) Dilution 
Anti-mouse Ig-HRP Rabbit Dako (P0260) 1:2000 
Anti-rabbit Ig-HRP Swine Dako (P0217) 1:2000 
Anti-goat Ig-HRP Rabbit Dako (P0449) 1:1500 
 
2.4.6 Stripping proteins from nitrocellulose membranes 
    Nitrocellulose membranes were incubated in stripping solution (Restore Plus 
Western Blot Stripping Buffer, Thermo Fisher Scientific, Rockford, USA) for 8 min 






2.5 TNF- and IL-6 ELISA 
    TNF- and IL-6 secretion into culture medium was quantitated using ELISA kits 
(R&D Systems, UK) according to the manufacturer’s instructions. Recombinant 
standard solutions and 1:4 dilutions of samples were prepared, and 50 µl/well 
standard or sample was added to a 96-well plate and incubated at room temperature 
for 2 hr. The plate was washed four times with wash buffer, 100 µl/well HRP-
conjugated secondary antibody was added and the plate was incubated at room 
temperature for 2 hr. The plate was washed five times with wash buffer, 100 µl/ well 
substrate solution was added, and the plate was incubated for up to 30 min at room 
temperature. After this time, 100 µl stop solution was added. The optical density at 
450 nm was measured within 30 min using a microplate reader (Model 550, Bio-Rad, 
Hemel Hempstead, UK), with the correction wavelength set to 570 nm. 
 
2.6 Cell migration assay 
    Cell migration was measured using a transwell assay with 24-well transwell 
chambers (Corning, NY) described previously (Kanellis et al., 2004). Culture 
medium (600 µl) medium with or without 200 ng/ml recombinant murine MCP-1 
(PeproTech, USA) was placed in the lower wells of chambers and 100 µl cell 
suspension was added to upper wells (Fig. 2.1A). Upper and lower wells were 
separated by polyvinylpyrrolidone-free polycarbonate filters (5 µm pore size, 6.5 mm 
insert diameter). Transwell chambers were incubated at 37°C in 5% CO2 for 90 min. 
The upper surfaces of the membranes were then washed three times with cold PBS to 
remove cells that had settled on the separated upper surface of the separated. Cells 
trapped in the filter pores or adhering to the underside of the membrane were fixed in 
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cold methanol, stained with haematoxylin solution (Fluka) and counted (Fig. 2.1B). 
The total number of cells trapped in the pores was counted for each well. 
 
Figure 2.1. Diagram of the cell migration assay. (A) A transwell insert showing cell 
migration through a permeable membrane of 5 µm pore size. (B) After incubation, the 




2.7 Flow cytometry analysis 
    Flow cytometry was performed following transfections with Trib1 or scrambled 
control siRNA or with pmaxGFP plasmid (Chapter 2.3) to determine transfection 
efficiency and cell viability.  
2.7.1 Cell viability and transfection efficiency 
    Briefly, cells were washed with PBS, detached from the well surface and 
centrifuged at 300×g, 4°C for 5 min. Cell pellets were resuspended in 1 ml PBS, 
transferred to flow cytometer tubes and stored on ice until analysed. Flow cytometer 
analysis was performed using a BD FACSCalibur Flow Cytometer (BD Biosciences, 
San Jose, California, USA) using FITC and PE propidium iodide (PI) channels. For 
each sample 10,000 events were counted, and then 0.2 mg/ml PI was added to the 
Transwell insert








cell suspension to a final concentration of 50 μg/ml in order to stain dead cells. A 
further 10,000 events were then counted. Data were analysed using FACSDiva 
software version 5.02 (Becton Dickinson-Biosciences, USA) and transfection 
efficiency and cell viability were determined for each sample. 
2.7.2 Cell cycle analysis 
    Trib1-silenced and untransfected RAW264.7 cells were harvested by 
centrifugation at 300×g rpm for 5 min and resuspended in 1 ml cold PBS. Ice-cold 
100% ethanol (3ml) was added to the cells, providing a final concentration of 
approximately 70% (v/v) ethanol, and mixed by vortexing. Samples were incubated 
on ice for at least 30 min, and then cells were washed twice with PBS. After 
centrifugation at 500×g, the supernatant was carefully decanted. RNase (50 µl of a 
100 µg/ml solution) was added, and samples were flicked gently to mix and then 
incubated at 37°C for 15 min. Lastly, 200 µl PI was added to a final concentration of 
40 µg/ml. For the analysis, only signals from single cells were considered and 10,000 
cells were assayed for each sample. 
2.7.3 Detection of Annexin V-FITC and PI staining 
    Apoptosis and necrosis of RAW264.7 cells was determined by Annexin V-FITC 
and PI staining using a BD Annexin V-FITC apoptosis kit. After transfection (72 hr), 
1×105 cells were incubated with 5 µl Annexin V (20 µg/ml in 1× binding buffer) and 
5 µl PI (50 µg/ml in 1× binding buffer) for 15 min in the dark at room temperature. 
Next, 400 µl of 1× binding buffer was added to each tube and the samples were 





2.8 Statistical analyses 
    Linear mixed effect (LME) models were used to analyse the data presented in this 
thesis. According to the classification of Paterson (2003), datasets containing 
repeated measurement in a single experiment fit this model (Paterson S and Lello J, 
2003). The reason for choosing this model is that datasets were not independent in 
the experimental design, which involved repeated measurements of duplicate cell 
samples within a single experiment. The mixed model contains both fixed effects and 
random effects. A fixed effect compares measurement, for example of TNF- 
stimulation by different immune modulators, in a single group and the random effect 
is important for correcting errors within a group (experiment) or between wells 
(some experiments are done using multiwell plates). For some datasets, for example 
all qPCR results and the optimisation of TNF- production, Log2/Log10 
transformation was necessary to normalise the residuals before analysis. 
    Standard post-hoc (Tukey) tests were used for pair-wise comparisons of all 
treatments. 
    In addition to LME models, generalised LME models were used to analyse data in 
this thesis, in particular the count data in Chapter 5. The migrated cell counts were 
fitted using the Poisson process. Fixed effects were groups (untransfected cells, or 
cells transfected with scrambled or Trib1 siRNA) and random effects were 
introduced by different wells within an experiment. For the cell cycle analysis, the 
percentage of cells through FACS sorting was G1/S/G2M phase and we used 
Binomial process. For Tables 5.1, 5.2 and 5.3, the percentage apoptosis analysis used 
Pearson’s Chi-squared test and p <0.05 compared to the vehicle controls (vector or 




    Data was analysed using the free statistical software environment R (The R 
Foundation, Software version 2.14.1, Copyright (C) 2011, Vienna, Austria). In all 
cases, a p-value of <0.05 was considered to be statistically significant. All graphs and 




Chapter 3: Expression profiles of Trib family members during 
inflammatory responses in RAW264.7 cells 
Abstract 
    Macrophages comprise one of the major effector cell populations of the innate 
immune system. TLRs recognise a variety of microbial components and mediate 
downstream signalling pathways such as NF-B and MAPK. IL-10 is an anti-
inflammatory cytokine that suppresses macrophage function; in contrast, IFN- is a 
potent macrophage activator. Trib family members have been implicated in 
regulating inflammatory responses. To clarify the function of Trib family members in 
TLR-induced inflammation in the presence of pro- or anti-inflammatory cytokines, 
RAW264.7 cells were treated with TLR2/9 ligands in the presence or absence of    
IL-10 or IFN-. High basal levels of Trib1 expression were observed in RAW264.7 
cell. TNF- production was used as an indicator of RAW264.7 cells activation. Real-
time PCR experiments showed that Trib1 expression was increased following 
treatment with TLR2/9 ligands, whereas IL-10-induced Trib1 expression was low.     
    In this chapter, I demonstrate that Trib1 is expressed in RAW264.7 cells and might 





    Macrophages are key components of inflammatory responses and much is known 
of the signalling pathways that are activated in macrophages in response to pro-
inflammatory and inhibitory stimuli, such as microbial infections. Moreover, 
macrophages and other components of the innate immune system have an important 
additional role in activating adaptive immunity (Gordon, 2003). After myeloid cells 
differentiate to form macrophages, they express different surface markers. For 
instance, CD11b is specifically expressed on both murine and human macrophages, 
whereas CD11c is specifically expressed on human macrophages (Gordon and 
Taylor, 2005). Classical activated macrophages respond to two signals: IFN- and 
PAMPs (Farrar and Schreiber, 1993; McCoy and O'Neill, 2008; Medzhitov, 2001). 
Macrophage stimulation with IFN- induces direct killing microbial responses, as 
well as up-regulating antigen processing and presentation pathways (Pestka et al., 
1997; Schroder et al., 2006). PAMPs stimulate macrophage activation through TLRs, 
which induce the innate immune response (Medzhitov, 2001). In contrast, the 
macrophage response to IL-4, IL-13 or IL-10 is known as alternative activation or 
M2 macrophage activation (Mantovani et al., 2002; Mills et al., 2000). For example, 
TAMs that originate from blood monocytes and have been stimulated by factors such 
as IL-10 and TGF- are recognised to be M2 type macrophages. These stimulated 
TAMs secrete autocrine IL-10 and chemokines to suppress T cell-induced adaptive 
immunity (Mantovani et al., 2002; Pollard, 2004; Solinas et al., 2009). 
    IL-10 performs a unique role in negatively regulating immunity and inflammation, 
primarily through a mechanism involving the selective inhibition of the expression of 
pro-inflammatory genes encoding cytokines, chemokines and cell surface molecules, 
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such as B7 and ICAM-1. IL-10 also inhibits potent pro-inflammatory cytokines, such 
as TNF- (Moore et al., 2001), and inhibits constitutive and inducible expression of 
MHC class II on monocytes (Haddad et al., 2003). In addition, IL-10 inhibits the 
antigen presentation process in macrophages (Bailey et al., 2006; Haddad et al., 2003; 
Murray, 2006) (Fig. 3.1). 
                       
Figure 3.1. Polarisation of monocytes into M2 macrophages following IL-10 stimulation. 
Monocytes stimulated by IL-10 differentiate into M2 macrophages. Moreover, IL-10 inhibits 
pro-inflammatory cytokines and cell surface markers to promote tumour progression. 
 
    TLR9 is involved in the recognition of unmethlyated CpG motifs in bacterial DNA. 
TLR9 is expressed in the endosome. However, several studies have reported that 
CpG DNA is detected in the endosome following internalisation of bacterial DNA, 
thus allowing it to be bound by the TLR9 receptor (Hallman M, 2001; Kaisho and 
Akira, 2001; Takeuchi and Akira, 2010). Interestingly, TLR9-/- mice are deficient in 
several CpG DNA responses, including cytokine production by macrophages, B cell 
proliferation and DC maturation (Akira et al., 2001; Takeuchi and Akira, 2010). 
Furthermore, CpG DNA stimulates the production the Th1-polarizing cytokine IL-12 



















2003). TLR9 is also a sensor of DNA viruses that contain genomes rich in the CpG 
DNA motif. Therefore, TLR9 stimulation results in activation of inflammatory 
cytokines such as IL-12 and type I IFN secretion (Pasare and Medzhitov, 2004). 
    Three Trib gene family members have been identified in mammalian systems: 
Trib1, Trib2 and Trib3 (Hegedus et al., 2006). These mammalian Trib family 
members have been implicated in regulating in inflammation, cancer development 
and nutrient metabolism (Du et al., 2003; Iynedjian, 2005; Qi et al., 2006). 
Importantly, Trib1 exerts a pro-inflammatory role in human HeLa cells (Kiss-Toth et 
al., 2006). Consistent with this, Trib1 has been implicated in macrophage activation 
and negatively regulate C/EBP expression under conditions of LPS-induced 
inflammation (Yamamoto et al., 2007). However, how Trib family members regulate 
innate immunity and inflammation remain unclear. 
Aim 
    The questions addressed in this chapter are which Trib family members are 
expressed in macrophages; and Trib expression relates to TLR-induced responses in 
the presence of pro- or anti-inflammatory cytokines.    
    Conventional PCR was used to determine the expression profile of Trib family 
members in order to select the most highly expressed Trib gene for further study. 
TNF- production was used to measure macrophages activation levels. Finally, real-
time PCR was used to understand how the gene expression of Trib family members 






3.2 Experimental design 
Cell culture and stimulation scheme 
Cells were grouped as described in Table 2.1 and Fig. 3.2.  
 













3.3.1 Expression profile of Trib family members in RAW264.7 cells 
    RAW264.7 is a murine monocyte/macrophage cell line. The morphology of 
normal RAW264.7 cells includes a monocyte-like round appearance and 
macrophage-like features, such as cytoskeletal extensions (Fig. 3.3A). The 
expression patterns of Trib1, 2 and 3 in RAW264.7 cells were previously unreported. 
My PCR results indicated that RAW264.7 cells express Trib1 and Trib3 transcripts, 
but no detectable Trib2 (Fig. 3.3B, lane 1 and 3 vs. lane 2). Murine splenocytes were 
used to check that the primers were functional (Appendix A)(Ashton-Chess et al., 
2008). Following this, qPCR was used to examine the expression levels of Trib 
family members in RAW264.7 cells (Fig. 3.3C). The result indicated that Trib2 is not 
expressed in the RAW264.7 cells, consistent with the previous result (Fig. 3.3B). 
Furthermore, Trib1 expression was significantly higher than Trib3 expression in 
macrophages (p = 0.002; Fig. 3.3C). Therefore, further studies in this thesis focussed 












                                           
 






























































Figure 3.3. Morphology, Trib expression profile of Trib family members in RAW264.7 cells. 
(A) Morphology of normal RAW264.7 cells examined using an inverted microscope. The 
arrow indicated the monocyte-like cells and the arrowhead indicates a cell with a 
macrophage-like morphology. The scale bar represents 50 µm. (B) The expression profile of 
Trib1 (lane 1; 294 bp), Trib2 (lane 2; 221 bp) and Trib3 (lane 3; 246 bp) transcripts. Lanes 4 
and 5 contained RNA and water negative control samples. A housekeeping gene (GAPDH, 
472 bp) was used as an internal control for the PCR. (C) Expression profile of Trib1, 2 and 3 
in RAW264.7 cells. Total RNAs were subjected to qPCR. The values represent the mean ± 
SD calculated from triplicate wells and two independent experiments. The relative ddCt 
formula is provided in Chapter 2. The LME model was used for statistical analysis. This data 
required Log2 transformation to normalise the residuals before analysis. p<0.05 were 
indicated as significant difference. For further details, refer to sections 2.8. **p = 0.002, 
comparing Trib1 and Trib3 transcript levels. 
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3.3.2 Optimisation of IL-10, IFN-, TLR2 and TLR9 ligand concentrations 
required to stimulate RAW264.7 cells 
    Trib1 was more highly expressed than Trib3 in macrophages. Therefore, changes 
in Trib1 expression were measured in an inflammatory environment. This required 
using a macrophage activation marker as a control. It was previously reported that 
RAW264.7 cells up-regulated TNF- in response to treatment with  IFN- or LPS, 
indicated an TNF- is marker of RAW264.7 activation (Vila-del Sol, 2008). 
Consequently, TNF- production was used as an indicator of RAW264.7 cell 
activation in this thesis. 
 
    In order to determine the optimal concentrations of IL-10, IFN-, TLR2 and TLR9 
ligands for RAW264.7 cell stimulation, a dose response curve was established for 
each of these reagents and TNF- production was measured to determine 
macrophage activation (Figs. 3.4). 
 
    The effect of IL-10 treatment is shown in Fig 3.4A, in which an increasing dosage 
of IL-10 resulted in a small but significant increase in TNF- production (basal 
levels were 390 pg/ml). Based on this result, a high concentration (10 ng/ml) was 
used for subsequent IL-10 treatments. IFN- treatment of RAW264.7 cells led to a 
large increase in TNF- production, even at the lowest concentration of 0.1 ng/ml 
IFN- (p <0.001, compared to basal levels). All concentrations of IFN- resulted in a 
significant increase in TNF- production. Maximal TNF- production (1660 pg/ml) 
was induced following stimulation with 1.0 ng/ml IFN- (Fig 3.4B); therefore, this 
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dose was selected for all subsequent IFN- cell treatments throughout the thesis. 
    In contrast, TLR2L and TLR9L treatments induced dramatic and statistically 
significant increases in TNF- production over basal levels even at low 
concentrations, for example 1 ng/ml TLR2L (7500 pg/ml TNF-) and 1 nM of 
TLR9L (4500 pg/ml TNF-; Figs 3.4C, D). Therefore, these low concentrations of 
TLR2L and TLR9L were chosen for all subsequent cell treatments.  
     
 
Figure 3.4. TNF- production in the mouse macrophage RAW264.7 cells induced by anti- 
and pro-inflammatory signals. RAW264.7 cells (2×105 cells/ml) were cultured in DMEM 
medium supplemented with 10% FCS overnight and then stimulated with different 
concentrations of IL-10 (A), IFN-, (B), TLR2 (C) and TLR9 (D) ligands, as indicated. After 
24 hr, cell supernatants were collected and TNF- production was determined by ELISA. 
Values represent the mean ± SD calculated from two independent experiments, each 
consisting of triplicate samples in two culture plates. For details of the statistical analysis, 
see sections 2.8. The analysis examined TNF- production and random effects were plates 
within experiment. The statistical analysis for TLR2L and TLR9L treatments required Log10 









































































    In the following experiments, cell numbers were optimised to 2x105 cells/well and 
prior to stimulation, cells were plated at this density, incubated overnight and then 1 
ml culture medium from each well was replace by 1 ml fresh medium containing 
cytokines or TLR ligands at the concentrations shown in Table 3.1. 
 
Table 3.1. Optimised concentrations of the immune modulators used in this study 
Immune modulator Concentration 
untreated - 
IL-10 10 ng/ml 
IFN- 1.0 ng/ml 
TLR9 ligand (ODN1826 CpG DNA) 1 nM 
IL-10 + TLR9L IL-10 (10 ng/ml) / TLR9L(1 nM) 
IFN- + TLR9L IFN- (1.0 ng/ml) / TLR9L (1 nM) 
TLR2 ligand (Pam3CSK4) 1 ng/ml 
IL-10 + TLR2L IL-10 (10 ng/ml) / TLR2L (1 ng/ml) 




3.3.3 TNF- production is a marker of RAW264.7 cell activation 
    Using TNF- production as an indicator of activation, RAW264.7 cells were 
treated with immune modulators at the optimal concentrations indicated in the 
previous result. Treatment with IL-10 (10 ng/ml), IFN- (1.0 ng/ml), TLR2L (1.0 
ng/ml) and TLR9L (1nM) resulted in a significant increase in TNF- production 
compared with untreated cells. Cell culture supernatants were collected at 24 hr and 
48 hr after treatment (Fig 3.5). 
 
    After 24 hr, TNF- production in all treated cells was significantly increased 
compared to untreated controls. Combined treatments, such as IFN- with TLR2L, 
did not show a synergistic effect (for TLR2L single treatment compared with 
combined treatment, p = 0.981). Conversely, combined IFN- and TLR9L treatment 
led to a decrease in TNF- production (TLR9L single treatment compared with 
combined treatment, p < 0.001). Additionally, in groups treated with combined IL-10 
and TLR2L or TLR9L, there was a significantly increased TNF- production 
compared with IL-10 single treatment (p < 0.001). This result was consistent with the 
previous result (Fig. 3.4) and confirms TNF- production to be an activation marker 
for RAW264.7 cells. 
 
    However, after 48 hr, TNF- production was significantly increased in all 
treatment groups relative to untreated cells, except for combined IL-10/IFN- and 
TLR9L treatment (p = 0.651 and p = 0.649, respectively). More interestingly, 
comparing 24 hr and 48 hr treatment times revealed that TNF- production was 
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significantly increased by IL-10 (p <0.001), TLR2L (p <0.001), IL-10 combined with 
TLR2L (p <0.001), IFN- combined with TLR2L (p <0.001) treatment. A significant 
reduction in TNF- production resulted from treatment with IFN- (p <0.001), 
TLR9L (p <0.001), IL-10 combined with TLR9L (p <0.001) and IFN- combined 






Figure 3.5. Kinetics of TNF- production by RAW264.7 cells following stimulation with 
pro- and anti-inflammatory cytokines. TNF- production in RAW 264.7 cells was measured 
at 24 hr and 48 hr post-stimulation. RAW264.7 cells produced low basal levels of TNF-. 
Values represent the mean ± SD of three independent experiments each consisting of 
triplicate samples in two culture plates. Log10 transformation was required. A standard post-
hoc (Tukey) test was used to carry out pair-wise comparisons of all treatments. *, p <0.001 
comparing each treatment to untreated controls after 24 hr; **, p <0.001 comparing each 
treatment to untreated controls after 48 hr; +, p <0.001 comparing 24 hr treatment to that of 
48 hr. For details of the statistical analysis, see sections 2.8. 






































3.3.4 Changes in RAW264.7 cell morphology following stimulation by IL-10 or   
IFN- combined with TLR2/9 ligands 
 
    RAW264.7 cells were plated at 2x105 cells/ml in 24-well plates, incubated 
overnight and then stimulated by immune modulators (see Table 3.1). 
 
    Microscopic analysis of RAW264.7 cell morphology revealed differences between 
control (Fig. 3.6A) and stimulated cells, and also between cells treated with single 
treatment (Fig. 3.6) and combined treatments (Fig. 3.7). 
 
    Following IL-10 and TLR9L single treatments (Fig. 3.6B, E), most cells presented 
a smaller, more rounded phenotype with few cytoplasmic extensions as the similar 
phenotype as control (Fig. 3.6A). In contrast, following single treatment with IFN- 
(Fig. 3.6C) and TLR2L (Fig. 3.6D), RAW264.7 cells were larger and exhibited 
numerous cytoskeletal extensions. 
 
    RAW264.7 cells subjected to combined IL-10/TLR2L or IL-10/TLR9L treatments 
displayed the same phenotype as cells treated with IL-10 alone (Fig. 3.7A, C). 
However, RAW264.7 cells treated with IFN- combined with TLR2L showed strong 
spreading, cytoskeletal projections and membrane ruffling (Fig. 3.7B, arrow). This 
phenotype was observed in cells treated with combined IFN- and TLR9L (Fig. 3.7D) 









Figure 3.6. Morphology of RAW264.7 cells after stimulation with different immune 
modulators . RAW264.7 cells were untreated (A) and treated with (B) IL-10, (C) IFN-, (D) 
TLR2 ligands and (E) TLR9 ligands for 24 hr, and then digital images were captured using 
an Exwave HAD 3CCD colour video camera mounted on an inverted microscope. 
Concentrations of immune modulators are shown in Table 3.1. The scale bar represents 50 
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Figure 3.7. Morphology of RAW264.7 cells after stimulation with different treatment 
combinations. RAW264.7 cells were treated for 24 hr with (A) IL-10 plus TLR2 ligands, (B) 
IFN- plus TLR2 ligands, (C) IL-10 plus TLR9 ligands and (D) IFN- plus TLR9 ligands, 
and then digital images were captured using an Exwave HAD 3CCD colour video camera 
mounted on an inverted microscope. Concentrations of the immune modulators are shown in 
Table 3.1. The scale bar represents 50 µm. Arrowheads indicate monocyte-like macrophages, 
and arrows indicate cells with increased spreading, more cytoskeletal characteristics and a 
macrophage-like morphology.  
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3.3.5.1 IL-10 and TLR9 ligands transiently up-regulate Trib1 expression in 
RAW264.7 cells 
 
    Real-time PCR was used to study the time course of Trib1 expression in 
RAW264.7 cells following combined IL-10/TLR9L and IL-10/TLR2L treatment. 
 
    Optimised concentrations of immune modulators were added to RAW264.7 cells 
and total RNAs were extracted after 0.5, 1, 3, 6, 8 and 24 hr. Untreated controls were 
used to establish baseline Trib1 expression, which did not vary over the time course. 
 
    In general, IL-10 and TLR9L did not induce a high level of Trib1 expression over 
the course of the experiment. Only at the 1 and 3 hr time points did IL-10 treatment 
induce a significant increase in Trib1 expression over the baseline (Table 3.2; p = 
0.002 and p = 0.04, respectively). In contrast, IL-10 down-regulated of Trib1 
expression after 30 min (p <0.001), 6 hr (p = 0.001), 8 hr (p = 0.001) and 24 hr (p 
<0.001). 
 
    TLR9L single treatment rapidly up-regulated Trib1 expression after 1 hr compared 
to untreated cells (p = 0.002), but did not significantly down-regulate Trib1 
expression at 0.5, 6, 8 and 24 hr time points compared to untreated cells (p >0.10). 
Surprisingly, following combined treatment with IL-10 and TLR9L, Trib1 expression 






    Thus, in the presence of both IL-10 and TLR9L, Trib1 expression was low, but 





Figure 3.8 (A). Timecourse of Trib1 expression in treated RAW264.7 cells. RAW264.7 cells 
were stimulated with IL-10 in the presence or absence of TLR9 ligands for different times. 
Total RNA was extracted from cells of each treatment group and Trib1 expression was 
measured by qPCR. Values comprise the mean ± SD of three independent experiments done 
in triplicate. Trib1 expression was normalised to mGAPDH expression and the relative ddCt 
formula is described in Chapter 2. Relative Trib1 mRNA expression was compared to a 
calibrator, the zero time point. Statistical analysis is described in sections 2.8. LME was used 
to examine Trib1 ddCt relative to treatment, and random effects were experiment. All data 
required Log2 transformation to normalise the residuals pre-analysis. A standard post-hoc 
(Tukey) test was used to carry out pair-wise comparisons of all treatments. In all cases, p 
<0.05 relative to the untreated group was considered to indicate statistical significance. 



















































Table 3.2. Statistical analysis of Trib1 expression following treated single or dual 
treatment with IL-10 and TLR9L 
Comparison 0.5 hr 1 hr 3 hr 6 hr 8 hr 24 hr 
Untreated 
vs. IL-10 
p <0.001 p <0.01 p <0.05 p <0.01 p <0.01 p <0.001 
Untreated 
vs. TLR9L 
p = 0.982 p <0.01 p = 0.274 p = 0.130 p = 0.168 p = 0.891 
Untreated 
vs. dual 
p = 0.288 p = 0.909 p = 0.693 p = 0.338 p = 0.379 p = 0.943 
IL-10 vs. 
TLR9L 
p <0.001 p = 0.909 p = 0.834 p = 0.476 p = 0.396 p <0.05 
IL-10 vs. 
dual 
p = 0.07 p <0.001 p = 0.409 p <0.001 p = 0.17 p <0.01 
TLR9L vs. 
dual 
p = 0.502 p <0.001 p = 0.896 p <0.001 p = 0.968 p = 0.998 
 
3.3.5.2 TLR2 ligands induce high levels of Trib1 expression in RAW264.7 cells 
 
    Conversely, when RAW264.7 cells were treated with TLR2L, Trib1 expression 
was potently induced, reaching maximal expression peak after 30min (Fig. 3.8B), 
and then decreasing between 1hr and 24 hr. From 30 min to 6 hr after treatment, 
Trib1 expression was significantly higher than in untreated controls (Table 3.3; p 
<0.002). After 24 hr, Trib1 expression was lower than baseline (p <0.001). 
 
    Combined TLR2L and IL-10 treatment up-regulated Trib1 transcripts from 30 min 
onwards, reaching a peak after 3 hr (Trib1 expression at 30min, 1hr and 3hr time 
points were above basal levels, p <0.001) and followed by a gradual decrease after 6 
hr and a return to basal levels (Fig. 3.8B; p <0.01). After 24 hr, Trib1 expression was 
lower than in untreated cells, but not significantly (p = 0.06). 
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    In contrast to TLR9L, TLR2L treatment induced a rapid, high level of Trib1 
expression from 30 min to 6 hr. Further, combined IL-10 and TLR2L treatment 
reduced Trib1 expression from 30min to 3 hr. 
 
 
Figure 3.8 (B). Timecourse of Trib1 expression in treated RAW264.7 cells. RAW264.7 cells 
were stimulated with IL-10 in the presence or absence of TLR2 ligands for different times. 
Total RNA was extracted from cells of each treatment group and Trib1 expression was 
measured by qPCR. Values comprise the mean ± SD of three independent experiments done 
in triplicate. Trib1 expression was normalised to mGAPDH expression and the relative ddCt 
formula is described in Chapter 2. Relative Trib1 mRNA expression was compared to a 
calibrator, the zero time point. Statistical analysis is described in sections 2.8. LME was used 
to examine Trib1 ddCt relative to treatment, and random effects were experiment. All data 
required Log2 transformation to normalise the residuals pre-analysis. A standard post-hoc 
(Tukey) test was used to carry out pair-wise comparisons of all treatments. In all cases, p 
<0.05 relative to the untreated group was considered to indicate statistical significance. 























































Table 3.3. Statistical analysis of Trib1 expression following single or dual treatment 
with IL-10 and TLR2L 
Comparison 0.5 hr 1 hr 3 hr 6 hr 8 hr 24 hr 
Untreated 
vs. IL-10 
p <0.001 p <0.01 p <0.05 p <0.01 p <0.01 p <0.001 
Untreated 
vs. TLR2L 
p <0.001 p <0.001 p <0.001 p <0.01 p = 0.969 p <0.001 
Untreated 
vs. dual 
p <0.001 p <0.001 p <0.001 p <0.01 p = 0.949 p = 0.063
IL-10 vs. 
TLR2L 
p <0.001 p <0.001 p <0.001 p <0.001 p <0.05 p = 0.819
IL-10 vs. 
dual 
p <0.001 p <0.01 p <0.001 p <0.001 p <0.001 p = 0.794
TLR2L vs. 
dual 
p <0.001 p <0.01 p = 0.492 p = 0.956 p = 0.754 p = 0.277
 
              
3.3.6.1 IFN- strongly induces Trib1 expression in RAW264.7 cells 
    Stimulation of RAW264.7 cells with IFN- induced a high level of Trib1 
expression. Trib1 transcript expression was up-regulated from 1 hr onwards, with a 
peak of expression at 3 hr, followed by a decrease to baseline after 8 hr (Fig. 3.9A). 
Between 1 hr to 6 hr, IFN--induced Trib1 expression was significantly higher in 
untreated cells (p <0.001, p <0.001 and p <0.001 for 1hr, 3hr and 6hr samples, 
respectively, Table 3.4). 
 
    Treatment with TLR9L alone induced a rapid up-regulation of Trib1expression 
after 1 hr (p = 0.002), tailing off from 3 hr to 8 hr. However, Trib1 expression was 
not significantly down-regulated after 6 hr, 8 hr or 24 hr compared to untreated cells 
(Fig. 3.9A; p >0.10). 
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    Interestingly, dual IFN-/TLR9L treatment restored the expression profile to that 
seen following IFN- treatment alone. After 6 hr, IFN--induced Trib1 expression 
was significantly higher than in the dual treatment group (p = 0.04). Therefore, 
compared with IL-10-induced Trib1 expression (Fig. 3.8), IFN- up-regulated Trib1 
expression was from 1 hr to 6 hr. 
 
Figure 3.9 (A). Timecourse of Trib1 expression in treated RAW264.7 cells. RAW264.7 cells 
were stimulated with IFN- in the presence or absence of TLR9 ligands for different times. 
Total RNA was extracted from cells of each treatment group and Trib1 expression was 
measured by qPCR. Values comprise the mean ± SD of three independent experiments done 
in triplicate. Trib1 expression was normalised to mGAPDH expression and the relative ddCt 
formula is described in Chapter 2. Relative Trib1 mRNA expression was compared to a 
calibrator, the zero time point. Statistical analysis is described in sections 2.8. LME was used 
to examine Trib1 ddCt relative to treatment, and random effects were experiment. All data 
required Log2 transformation to normalise the residuals pre-analysis. A standard post-hoc 
(Tukey) test was used to carry out pair-wise comparisons of all treatments. In all cases, p 
<0.05 relative to the untreated group was considered to indicate statistical significance. 






















































Table 3.4. Statistical analysis of Trib1 expression following single or dual treatment 
with IFN- and TLR9L 
Comparison 0.5 hr 1 hr 3 hr 6 hr 8 hr 24 hr 
Untreated 
vs. IFN- 
p = 0.937 p <0.001 p <0.001 p <0.001 p = 0.117 p = 0.775
Untreated 
vs. TLR9L 
p = 0.982 p <0.01 p = 0.274 p = 0.130 p = 0.168 p = 0.891
Untreated 
vs. dual 
p = 0.986 p <0.001 p <0.001 p <0.001 p = 0.998 p = 0.90 
IFN- vs 
TLR9L 
p = 0.774 p <0.001 p <0.001 p <0.001 p <0.05 p = 0.52 
IFN- vs. 
dual 
p = 0.998 p = 0.171 p = 0.617 p <0.05 p = 0.281 p = 0.378
TLR9L vs. 
dual 
p = 0.851 p = 0.201 p <0.001 p <0.001 p = 0.554 p = 0.996
 
3.3.6.2 IFN- combined with TLR2 ligands enhance Trib1expression in 
RAW264.7 cells 
    According to the previous result (Fig.3.8B), Trib1 expression is strongly increased 
in RAW264.7 cells following TLR2L treatment, peaking after 30 min (Fig. 3.9B). 
 
    Combined IFN- and TLR2L treatment induced a similar expression pattern to that 
with IFN- alone, with increased expression along with an earlier peak of expression 
(Fig. 3.9B; from 3 hr to 1 hr). From 30 min to 6 hr, Trib1expression induced by 
combined treatment was significantly higher than in untreated controls (Table 3.5; p 
<0.001), but decreased to baseline at the 8 hr and 24 hr time points (p >0.10 for both 
relative to basal levels). After 24 hr, Trib1expression had returned to basal levels for 
all three treatments. 
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    From another perspective, the TLR2L-induced peak of Trib1 expression occurred 
after 30 min and was significantly higher than the basal and IFN--induced 
expression, as well as Trib1 expression following combined treatment (p <0.001 for 
all). At this time point, the Trib1 expression following combined treatment was 
higher than in cells treated with IFN- alone (p <0.001). For dual treatment-induced 
Trib1 expression, the time point for maximal expression was 1 hr and expression 
levels were higher than in cells treated with IFN- alone (p = 0.004), but was not 
significantly different from TLR2L-treated cells (p = 0.298). After 3 hr, IFN--
induced Trib1 expression was higher than in cells subjected to combined treatment (p 
<0.001), but was not significantly different from in expression in TLR2L-treated 
cells (p = 0.111). 
 
    Thus, following stimulation with IFN- and TLR2L, Trib1 expression is strongly 






Figure 3.9 (B). Timecourse of Trib1 expression in treated RAW264.7 cells. RAW264.7 cells 
were stimulated with IFN- in the presence or absence of TLR2 ligands for different times. 
Total RNA was extracted from cells of each treatment group and Trib1 expression was 
measured by qPCR. Values comprise the mean ± SD of three independent experiments done 
in triplicate. Trib1 expression was normalised to mGAPDH expression and the relative ddCt 
formula is described in Chapter 2. Relative Trib1 mRNA expression was compared to a 
calibrator, the zero time point. Statistical analysis is described in sections 2.8. LME was used 
to examine Trib1 ddCt relative to treatment, and random effects were experiment. All data 
required Log2 transformation to normalise the residuals pre-analysis. A standard post-hoc 
(Tukey) test was used to carry out pair-wise comparisons of all treatments. In all cases, p 
<0.05 relative to the untreated group was considered to indicate statistical significance. 
























































Table 3.5. Statistical analysis of Trib1 expression following single or dual treatment 
with IFN- and TLR2L. 
Comparison 0.5 hr 1 hr 3 hr 6 hr 8 hr 24 hr 
Untreated 
vs. IFN- 
p = 0.937 p <0.001 p <0.001 p <0.001 p = 0.117 p = 0.775 
Untreated 
vs. TLR2L 
p <0.001 p <0.001 p <0.001 p <0.01 p = 0.969 p <0.001 
Untreated 
vs. dual 
p <0.001 p <0.001 p <0.001 p <0.001 p = 0.957 p = 0.955 
IFN- vs. 
TLR2L 
p <0.001 p = 0.364 p = 0.128 p <0.001 p <0.05 p <0.001 
IFN- vs. 
dual 
p <0.001 p <0.01 p <0.001 p <0.05 p <0.05 p = 0.455 
TLR2L vs. 
dual 
p <0.001 p = 0.298 p = 0.111 p = 0.60 p = 0.998 p <0.05 
 








    In this chapter, I sought to measure the expression profiles of Trib family members 
and to determine how Trib1 expression changes in response to stimuli in 
macrophages. For this, I used reverse-transcription PCR (RT-PCR) to show that 
Trib1 and Trib3 were expressed in RAW264.7 myeloid cells, but that Trib2 was not. 
Moreover, qPCR demonstrated that Trib1 expression was higher than Trib3; 
therefore, Trib1 expression was assessed in subsequent experiments. Moreover,   
IFN- and TLR2 ligands induced high levels of Trib1 expression from 30 min to 6 hr, 
whereas IL-10 and TLR9 ligands induced weaker Trib1 expression. 
 
    Trib1 and Trib3 were expressed in RAW264.7 cells (Fig. 3.3B), in agreement with 
a previous report that Trib1 and Trib3 are expressed in monocytes (Ashton-Chess et 
al., 2008). Moreover, the discovery that Trib2 is not expressed in RAW264.7 cells 
(Fig. 3.3B) suggests that Trib2 is not expressed in immortalised cell line. The 
expression profiles of Trib family members showed that each Trib family member 
exhibits cell-type specificity, also consistent with previously studies (Ashton-Chess 
et al., 2008; Sung et al., 2006). 
 
    The second aim of this chapter was to identify a good macrophage activation 
marker following TLR2/9 ligands and IL-10/IFN- stimuli. Moreover, the effective 
concentrations of these immune modulators were established for further experiments. 
I identified TNF- production to be an effective indicator for these stimulators.  
TNF- is a pro-inflammatory cytokine that is mainly up-regulated by activation of 
the NF-B pathway (Jongeneel, 1994). Dose response curves showed a statistically 
85 
 
significant induction of TNF- following IFN- treatment (Fig. 3.4B and Fig. 3.5). 
Most IFN- signalling occurs through activation of the STAT1 pathway, and not the 
NF-B pathway (Lang, 2005). Hence, the increase in TNF- production is probably 
not a direct result of IFN- stimulation, but instead may occur through activation of 
NF-B by IFN-responsive genes (Lang, 2005). A greater increase in TNF- 
production was seen following treatment with TLR2L and TLR9L, especially TLR2L. 
TLR2 receptor signalling leads to MAPK activation, which directly activates the  
NF-B signalling pathway (Krishnan et al., 2007). Although TLR9 receptor 
signalling preferentially activates the Interferon Regulatory Factor 7 (IRF7) pathway, 
the NF-B pathway is also activated to a lesser degree (Sabroe et al., 2008). The 
induction of NF-B-induced TNF- production by TLR signalling pathways was 
shown in Figs 3.4 and 3.5. Moreover, TLR2L-induced TNF- production was 
constitutive, since TNF- production remained high 48 hr after single or combined 
treatments. Conversely, combined IFN- and TLR2L treatment resulted in decreased 
TNF- production compared with TLR2L treatment alone. IFN- has been reported 
to inhibit TLR2L activation of the MAPK pathway in macrophages (Hu et al., 2006), 
which may explain my observations (Fig. 3.5). However, the same result was seen 
following combined treatment with TLR9L and IFN-, although crosstalk between 
IFN- and TLR9 has not been reported. 
 
    IL-10, an anti-inflammatory cytokine, cannot activate NF-B signalling and this is 
borne out by the reduced induction of TNF- production even in combined 
treatments. IL-10 inhibits the expression of MHC class II and the co-stimulatory 
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CD80/CD86 molecules in macrophages, and suppresses the production of pro-
inflammatory cytokines, such as IL-6, IL-12 and TNF- via the STAT-3 pathway 
(Haddad et al., 2003). In macrophages, low TNF- production is associated with   
IL-10 inhibition of the TNF gene through inhibition of transcriptional elongation 
(Smallie et al., 2010), which may in part explain my observation of low TNF- 
production in IL-10-treated cells (Fig. 3.4A and Fig. 3.5). I went on to investigate 
Trib1-associated signalling pathways in the next chapter. 
 
    My observations of RAW264.7 cell morphology indicated different stimulators 
induce various characteristics in macrophages. IL-10 treated macrophages (Fig 3.6B) 
are more monocyte-like than macrophage-like in appearance, indicating that IL-10 
cannot activate macrophages. In contrast, IFN-- and TLR2L- treated macrophages 
(Fig. 3.6 C, D) showed a strong activation, consistent with previous findings (Gordon, 
2003). The presence of pseudopodia and cytoplasmic extensions shows that there are 
more lysozymes and macrophages present and that cells are competent to undergo 
phagocytosis. Macrophage phagocytosis of microorganisms is important for host 
immunity, and activated macrophages kill ingested pathogens by the production of 
reactive oxygen and nitrogen metabolites (Gordon and Taylor, 2005). However, 
TLR9L-treated macrophages (Fig. 3.6E) retained a monocyte-like morphology, 
indicating that the concentrations of TLR9L used might not be sufficient to induce 
the macrophage activation. Interestingly, this morphological observation is consistent 
with TNF- production, which demonstrated that TLR2 ligands cooperate with   




    The main aim of this chapter was to explore Trib1 expression levels following 
stimulation with TLR2/TLR9 ligands and IL-10/IFN-. The qPCR results 
demonstrated that macrophage Trib1 expression is transiently up-regulated by IL-10 
after 1 hr and 3 hr, but is down-regulated at 0.5 hr, 6 hr, 8 hr and 24 hr time points 
(Figs. 3.8). IL-10 supresses macrophage activation (Haddad et al., 2003), and I 
observed that IL-10-induced Trib1 expression is very weak (Fig. 3.8). It is reasonable 
to speculate that Trib1 is associated with IL-10 which inhibits macrophage activation. 
Moreover, IL-10 is an autocrine cytokine in macrophages (Lang et al., 2002), and  
IL-10 treatment of differentiated macrophages results in decreased inflammation by 
induction of the inhibitory C/EBP protein (Csoka et al., 2007). Furthermore, 
C/EBP function is inhibited by Trib1 (Yamamoto et al., 2007). Therefore, it is 
important to determine whether IL-10 down-regulates Trib1 in macrophages, and 
whether Trib1 inhibits IL-10 production through C/EBP. It is possible that a 
negative feedback loop is involved in the suppression of Trib1 by IL-10, leading to 
macrophage deactivation (Gordon, 2003). Trib2 can suppress IL-10 synthesis in 
human monocyte-derived macrophages (Deng et al., 2009), which suggests that 
Trib1 also may suppress IL-10 in macrophages. Therefore, the precise mechanism 
whereby IL-10 suppresses Trib1 in macrophage remains to be determined. 
 
    The failure of TLR9L to induce Trib1 expression may be due to the concentration 
being too low or the time used for stimulating TLR9 being suboptimal. I chose 1nM 
TLR9L, as this was the optimal concentration for TNF- production (Fig. 3.4D). 
TLR9 is expressed in the endosome, and can therefore recognise endosomal CpG 
DNA following internalisation of bacterial DNA. The time required for 
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internalisation is greater than the time required for TLR2 response (Hallman M, 2001; 
Kaisho and Akira, 2001; Takeuchi and Akira, 2010). Therefore, it is important to 
measure different TLRs-mediated inflammation at the correct time point. 
 
    For microorganism infection, the first line of response is rapid and potent. When 
TLR2 ligands engage with TLR2 receptors, MyD88 is rapidly activated and TRAF6, 
MAPK and NF-B mediate the downstream production of pro-inflammatory 
cytokines and activate macrophages (Kaisho and Akira, 2001). I observed that 
macrophage Trib1 was up-regulated quickly (30 min) following treatment with TLR2 
ligands. Interestingly, combined IL-10 and TLR2L treatment resulted in rapid (within 
30 min) and extended Trib1 expression (up to 3 hr), followed by a decrease to 
baseline. This expression pattern was similar to the TLR2L single treatment, but with 
a lower degree of expression. IL-10 inhibition of TLR2L-induced inflammation has 
been reported in Yersinia pestis infections (Hu et al., 2006; Sing et al., 2002). 
Induction of IL-10 by TLR2L is proposed to play a role in suppression of host 
immune responses and it is possible that Trib1 might be involved in this process. 
 
    In addition, compared to TLR2L plus cytokine treatment, the Trib1 expression 
peak following IFN- treatment occurred after 3 hr. IFN- is a strong macrophage 
activator. This specific Trib1 up-regulation in macrophages treated with IFN- and 
TLR2L indicates that Trib1 contributes to innate immunity processes, such as 
macrophage activation, and also to microbial infection. Here, IFN- induced Trib1 
expression at a high level in macrophages, compared IL-10-induced Trib1 expression. 
This reinforces the possibility that Trib1 is associated with macrophage activation. 
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Therefore, induction of Trib1 expression is a consequence of pro-inflammatory 
activation of macrophages. 
 
    Immunoblots showed that the anti-Trib1 antibody was not specific (data not shown) 
and therefore I could not examine Trib1 protein expression in these cells. Therefore, 
in this study, only Trib1 mRNA results are presented. 
 
    Compared to IL-10- and IFN--induced Trib1 expression, Trib1 expression was 
very low following combined with TLR9L treatments. Conversely, IFN--induced 
Trib1 expression followed by TLR2L was strong. Hence, further experiments will 
only focus on the IFN- and TLR2L treatments. Moreover, as TLR2L and IFN- 
induced TNF- production through the MAPK pathway, they are more likely to link 
with Trib1. Therefore, in the following chapters, IFN-- and TLR2L induced Trib1 
expression will be evaluated. 
 
    To summarise this data, Trib1 is a macrophage marker and functions by triggering 
macrophages to be activated or deactivated by different signalling pathways in 
response to infection. Moreover, this data also highlighted a negative feedback loop 
between Trib1 and IL-10 in macrophages via TNF- production, which deactivates 
macrophage function. 
 
    The results of this chapter demonstrate that Trib1 is expressed in RAW264.7 cells. 
Moreover, the Trib1 responses in macrophages to pro- or anti-inflammatory 
cytokines in the presence of TLR2/9 ligand-induced inflammation are distinct. IL-10 
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induces weak Trib1 expression, indicating that IL-10 deactivation of macrophages 
may occur via Trib1 modulation. 
 
    In conclusion, Trib1 expression is influenced by pro-/anti-inflammatory cytokines 
and/or TLR ligand stimulation of RAW264.7 cells (Fig. 3.10). More details of this 




Figure 3.10. Summary of Trib1 expression in macrophages treated with TLR ligands, and 
cytokine-induced responses. (A) When macrophages are treated with IFN- and TLR2/9 
ligands, Trib1 expression is induced and TNF- production is increased, leading to 
macrophages activation. (B) Conversely, when macrophages are treated with IL-10 and 
TLR9 ligands, Trib1 expression is weak and TNF- production is low. Under these 




















Chapter 4: Silencing of Trib1 to investigate its biological function 
 
Abstract 
    Trib was first described in dog thyroid cells and its functions were identified in 
Drosophila in 2000. In mammalian systems, three members of the Trib family have 
been identified. They function as scaffold proteins to control the activity of signalling 
pathways, e.g., Trib1 regulates MAPK, NF-B and C/EBP. To investigate the role 
of Trib1 in the TLR-induced inflammatory response to pro-inflammatory cytokines, 
RAW264.7 cells were stimulated with TLR2 ligands in the presence or absence of 
IFN-. SiRNA-mediated Trib1 knockdown resulted in inhibition of C/EBP 
expression at the translational level in both stimulated and resting macrophage 
populations. TNF- production increased in Trib1-knockdown cells after treatment 
with IFN- and/or TLR2L, while IL-6 secretion remained unchanged. Finally, 
expression of ERK1/2 was reduced in Trib1 siRNA-treated cells. 
    In conclusion, these results suggest that Trib1 contributes to the pro-inflammatory 
response of macrophages by acting as a regulator of ERK1/2 and C/EBP during 




    Trib1 is a regulator of Toll/IL-1-induced downstream signalling and works as a 
scaffold protein to modulate MAPK signalling pathways (Hegedus et al., 2007; Kiss-
Toth et al., 2004). In Caenorhabditis elegans nematodes, the NIPI-3 kinase-like 
protein acts upstream of MAPK and has homology to human Trib1 (Pujol et al., 
2008). Up-regulation of Trib1 in vascular smooth muscle cells treated with IL-1 or 
LPS induces proliferation and chemotaxis via inhibition of the JNK pathway (Sung 
et al., 2007). Moreover, using Trib1-deficient macrophages it has been demonstrated 
that Trib1 negatively regulates C/EBP expression in TLR-mediated signalling. 
However, macrophages in which Trib1 has been deleted have the same levels of 
phosphorylated MAPKs (p38, JNK and ERK) and IB as normal macrophages 
(Yamamoto et al., 2007). Trib1 is also involved in C/EBP degradation during 
myeloid leukaemogenesis through a Trib1–MEK1 interaction (Yokoyama et al., 
2010). 
    The innate immune system responds to infection by producing pro-inflammatory 
mediators such as TNF- and IL-6 (Matsusaka et al., 1993). Conserved pathogen-
associated molecular patterns on microorganisms are recognised by TLRs, which 
mediate signals to activate immune cells via association with different intracellular 
adaptor proteins. Activation of TLR2 occurs after binding to the relevant ligands, 
such as bacterial lipoarabinomannan (LAM), bacterial lipoprotein (BLP) and 
peptidoglycans (PGN), as well as the yeast cell wall particle, zymosan (Takeda et al., 
2003). TNF- is a prototypical pro-inflammatory cytokine for which induction by 
TLRs is dependent on NF-B and MAPKs, and as well as on C/EBP and C/EBP 




                                
Figure 4.1. Regulation of TLR2 signalling pathway is mediated by C/EBP and , and 
MAPK. In addition to the well-known TLR2 signalling cascade (MyD88/TRAF/NF-κB), the 
C/EBP and C/EBP transcription factors are also trigger pro-inflammatory cytokine 
production. MyD88 is recruited activated TLRs, then binds to IRAK4, which activates 
C/EBP and C/EBP, leading to inflammatory gene expression. 
 
 
    IFN- influences LPS-dependent signalling by promoting ligand–receptor 
interactions, as well as by activating downstream signalling machinery. Many effects 
of LPS are mediated by the NF-B transcription factor. In the RAW264.7 
macrophage-like cell line, IFN- pre-treatment promotes rapid NF-B activation and 
degradation of the NF-B inhibitor, IB, upon LPS exposure (Adib-Conquy and 
Cavaillon, 2002; Tamai et al., 2003). Compared with TLRs, IFN- is a weak activator 
of MAPK, but can trigger activation of the MEK1/ERK1/2 pathway in a range of cell 
lines and primary cells (Hu et al., 2001; Hu et al., 2007b). 


















    When IFN- stimulates this pathway, two waves of ERK activation occur. An early 
wave (after approximately 30 min) leads to AP-1 activation independent of the JAK–
STAT1 pathway (Gough et al., 2007). A second pathway, necessary for STAT1 Ser727 
phosphorylation, is activated after longer (2 hr) exposure to IFN- (Hu et al., 2001) 
(Fig. 4.2). However, the ability of IFN- to activate the p38 and JNK pathways 
remains undetermined. Additionally, C/EBP-dependent gene transcription responds 
to IFN- through ERK1/2 (Hu et al., 2001). 
 
 
                  
Figure 4.2. IFN- activates a signalling through STAT-1 and MAPK. IFN-ɣ binds to IFNGR 
and JAK/TYK2, which are then phosphorylated. Most IFN- signalling occurs through 
STAT-1, which becomes phosphorylated at Tyr701 and is translocated into the nucleus, where 
it binds to the ISRE and GAS (ISRE/GAS) binding domain on the target genes such as MHC 
class I and II, leading to transcription. IFN- alternatively triggers the MAPK cascade, 
resulting in STAT-1 phosphorylation at Ser727. Finally, IFN- activates ERK1/2 mediated by 























    RNA interference (RNAi) was first described in the nematode Caenorhabditis 
elegans in 1998 (Fire et al.). Three years later, RNAi was described in mammalian 
cells by Tuschl and colleagues (Elbashir et al., 2001). RNAi induces post-
transcriptional gene silencing by targeting mRNA for degradation and thus inhibiting 
protein translation (Pai et al., 2005). Therefore, in recent years, RNAi-mediated gene 
knockdown techniques have been extensively used to investigate gene function. It is 
a powerful tool for assaying gene function in mammalian cell lines, particularly for 
identifying potential regulators of signalling pathways (Martin and Caplen, 2007). 
    Although the experiments described in Chapter 3 did not provide direct evidence 
that Trib1 regulates the MAPK pathway, as reported previously (Kiss-Toth et al., 
2004), the results suggested that Trib1 may be involved in regulating the MAPK 
pathway following IFN- and TLR2L treatment to modulate the expression, of genes, 
such as TNF-. Based on the literature, the biological functions of Trib1 are not clear, 
in particular the identity of signalling pathway triggered by Trib1 in macrophages in 
response to these stimuli. 
 
Aim 
    In this chapter, I sought to investigate the biological roles of Trib1 in activated 
macrophages. As the siRNA-mediated gene knockdown technique is a powerful tool 
for investigating gene function, the first part of this chapter describes experiments to 
identify the most efficient Trib1 siRNA sequence and concentration for obtaining 
optimal inhibition. Subsequent experiments used Trib1 gene knockdown to 
determine the biological functions of Trib1 in RAW264.7 cells and its interface with 
signalling pathways involved in the regulation of inflammation. 
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4.2 Materials, methods and experimental design 
The experimental design is summarised in Figure 4.3 
 
 
Figure 4.3. The experimental design in this chapter. 
 
4.2.1 Electroporation protocol 
    The RAW264.7 cell line was optimised for siRNA transfection efficiency, as 
determined by fluorescence microscopy and flow cytometry, and described in section 
2.3.1. Transfections were performed in duplicate in six well plates using three 
different siRNA sequences at three different concentrations (100 nM, 250 nM and 
500 nM) and the electroporation protocol described in section 2.3.1. In short, 
RAW264.7 cells were harvest and counted, and then 2×106 cells were placed in a 1.5 
ml microcentrifuge tube with appropriate concentrations of siRNA. The positive 
control plasmid, pmaxGFP, was co-transfected with siRNA in parallel by 
electroporation as described in section 2.3.1. Transfection efficiency was analysed by 
counting GFP-positive cells using FACS, and knockdown efficiency was analysed at 















4.3.1 Optimisation of siRNA concentrations for Trib1 knockdown 
    Firstly, in order to determine which commercial Trib1 siRNA was the most 
efficient, RAW264.7 cells were transfected with three different Trib1 siRNA 
sequences (Table 2.3) using the electroporation method (see sections 2.3.1, 4.2.1). 
 
    As suggested in the manufacturer’s instruction, 250 nM of siRNA was used for 
optimisation experiments. After 24 hr, all groups were treated with TLR2L for 1 hr 
(Fig. 4.3). RNA extracted from treated cells and the efficiency of gene knockdown 
was examined by qPCR. Trib1 gene expression in untransfected cells was normalised 
to a value of one (100%). The results showed that in RAW264.7 cells transfected 
with scrambled siRNA, relative Trib1 expression was 95% (Fig. 4.4A). Following 
transfection with three different Trib1 siRNA sequences combined with TLR2L 
treatment, Trib1 expression decreased to 72%, 35% and 50% respectively (Fig. 4.4A). 
The percentage knockdown using sequences 503 or 505 was significantly lower than 
the scrambled group (p <0.001) and the efficiency of gene knockdown by sequence 
503 was significantly higher than of sequence 505 (p <0.001). Compared with 
scrambled siRNA controls, sequence 503 suppressed up to 55% of Trib1 expression 
(Fig. 4.4A). 
 
    Secondly, RAW264.7 cells were co-transfected with commercial Trib1 siRNA and 
a GFP expression vector and then examined by FACS after 24 hr. The percentage of 
live cells following co-transfection with the three Trib1 siRNAs were 80%, 87% and 
80% (for 130, 503 and 505, respectively; Fig. 4.4B). The transfection efficiency was 
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not affected by different siRNA sequences (p >0.1). Based on these two sets of 
experiments, sequence 503 was chosen for all further Trib1 siRNA experiments. 
 
    Moreover, in order to identify the Trib1 siRNA concentration providing optimal 
gene knockdown, a dose response curve was determined for sequence 503 using the 
concentration range 100–500 nM. The results indicated that 250 nM and 500 nM 
exhibit the same degree of inhibition (34% and 38%, respectively, p = 0.059) 
(Fig.4.4C). Therefore, 250 nM of sequence 503 was found to provide optimal 
















































































































Figure 4.4. Optimisation of Trib1 siRNA-mediated gene knockdown. (A) Expression of 
Trib1mRNA in RAW264.7 cells was measured for three commercial Trib1 siRNAs at a 
concentration of 250 nM, and relative suppression was determined by qPCR. (B) The 
transfection efficiency of three Trib1 siRNAs co-transfected with GFP was examined by 
FACS. (C) The optimal concentration of sequence 503 for down-regulating Trib1 mRNA 
was determined by qPCR. This experiment was done on two separate occasions with similar 
results. For details of the statistical analysis, see sections 2.8. Fixed effects were scrambled 
siRNA in comparison with three siRNA sequences and concentrations and random effects 
were wells within experiment. This data required Log2 transformation to normalise the 
residuals before analysis. A standard post-hoc (Tukey) test was used to carry out pair-wise 
comparisons of all groups. In all cases, p <0.05 was considered to indicate a statistically 
significant difference between experimental groups.*, p <0.05 compared with scrambled 
siRNA; ** p <0.001; NS, not significant.  
  
 
    Untransfected cells had normal RAW264.7 morphology as described in Chapter 3, 
consisting of a round monocyte-like (arrowhead, Fig. 4.5A) or a macrophage-like 
shape (arrow, Fig. 4.5A). 
 
    RAW264.7 cells transfected with scrambled siRNA had a similar morphology to 
untransfected controls (Figs.4.5A and B). 
 
    Interestingly, after Trib1 silencing by siRNA, RAW264.7 cells developed a more 
monocyte-like morphology, becoming more rounded with reduced adhesion (Fig. 
4.5C), and were easily detached from the culture plate. Therefore, detached 
RAW264.7 cells were used in the cytocentrifuge smear analysis described in section 
2.3.2. Notably, in this smear picture RAW264.7 cells exhibit a monocyte-like, 




Figure 4.5. RAW264.7 cell morphology following siRNA transfection. (A) Untransfected 
controls, cells transfected with (B) scrambled siRNA or (C) Trib1 siRNA, and (D) floating 
cells Trib1 siRNA-treated cells prepared as cytocentrifuge smears. All photomicrographs 
show cells 24 hr post-transfection. Arrowheads indicate monocyte-like cells, whereas arrows 





    In order to determine whether Trib1 is an essential gene, cell viability was 
assessed after transfection. After 24 hr, the percentage of live cells in the 
untransfected group was 88.7% (Fig.4.6B). In the scrambled siRNA group was 
81.1%, and was 79.1% in the Trib1 siRNA group (including detached cells) (Figs. 
4.6 C and D; Table 4.1). Transfection efficiency of scrambled and Trib1 siRNA was 
comparable, indicating that cell uptake of these molecules is equivalent (Fig. 4.7 and 
Table 4.1). 
 
Table. 4.1. Transfection efficiency and viability of siRNA-treated cells 
 Scrambled 
siRNA 




84.8 ± 3.81 86.5 ± 5.09 p= 0.988 
Viability (%) 79.7 ± 1.23 78.4 ± 1.12 p= 0.991 
 
 
Figure 4.6. PI staining to assess viability of transfected RAW264.7 cells. (A) Untransfected 
cells without PI staining, and PI-stained (B) untransfected, (C) scrambled siRNA-transfected 
cells and (D) Trib1 siRNA-transfected cells24 hr post-transfection. Cells were stained with 
PI and viability was assessed by FACS. The M1 population represents live cells. 
Scrambled siRNA Trib1 siRNA








     
Figure 4.7. FACS determination of transfection efficiency. RAW264.7 cells were co-
transfected with scrambled or Trib1 siRNA, together with the GFP expression vector. (A) 
Untransfected cells, (B) cells expressing GFP, (C) cells co-transfected with scrambled siRNA 




    The last stage of Trib1 siRNA screening was to confirm that Trib1 siRNA 
specifically inhibits Trib1 gene expression. Expression of Trib1 and Trib3 were 
measured following transfection with Trib1 siRNA. As shown previously (Fig. 3.3B 
and C), Trib2 was not expressed in the RAW264.7 cells. Only Trib1 expression was 
inhibited by Trib1 siRNA (p <0.001). Trib3 expression of was not affected by Trib1 
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    Further, there was no difference in Trib3 expression in scrambled siRNA-treated 
and Trib1 siRNA-treated cells (Fig. 4.8, p = 0.081).  
 
 
                               
Figure 4.8. The specificity of Trib1 siRNA was assessed for three Trib transcripts by qPCR. 
After 24 hr transfection, the RAW264.7 cells were stimulated with TLR2L for 1 h. Two 
separate experiments were done and similar results were obtained for both. Values represent 
the mean ± SD calculated from data performed in two plates using triplicate wells. Statistical 
analysis was described in sections 2.8. p <0.05 indicates a statistically significant difference; 
**, p <0.001. 
  
    Previous results established the best commercial Trib1 siRNA sequence and 
inhibitory concentration, and the specificity of inhibition. Under the optimised 
conditions, Trib1 siRNA suppressed 55% of Trib1 gene expression (Fig. 4.4A). 
 
    The first part of this chapter was designed to establish the concentration of Trib1 
siRNA for investigating novel functions of Trib1 and identifying possible signalling 












































4.3.2 Trib1 inhibition mediates increased TNF- production 
    In Chapter 3, TNF- was used as a marker for RAW264.7 cell activation. The 
baseline TNF- production in untransfected cells and those transfected with 
scrambled siRNA were similar (287.5 pg/ml and 300.5 pg/ml, respectively). 
 
    After RAW264.7 cells were treated with different immune modulators, both 
scrambled and Trib1 siRNA treatment groups showed abundant TNF- production (p 
<0.001). Conversely, after Trib1 silencing, TNF- production was significantly 
higher than in the scrambled siRNA-untreated group (320.0 pg/ml vs. 300.5 pg/ml, p 
= 0.03; Fig. 4.9). 
 
    After exposure to different stimulatory signals, TNF- production increased in 
both scrambled and Trib1 siRNA groups. 
 
    TLR2L induced abundant TNF- production after Trib1 knockdown, as did 
combined treatment with TLR2L and IFN- (6967.9 pg/ml vs. 3314.9 pg/ml and 
8462.8 pg/ml vs. 3590.8 pg/ml, respectively, p <0.001). 
 
    Treatment with IFN- alone resulted in a small but significant increase in TNF- 
production in the Trib1 knockdown group, compared with the scrambled group, 
(2175.0 pg/ml vs. 896.9 pg/ml, p <0.001). This result demonstrates that Trib1 is 




                    
Figure 4.9. Knockdown of Trib1 modulates TNF- production in RAW264.7 cells. TNF- 
production in transfected cells was measured 24 hr post-stimulation. Values represent the 
mean ± SD in triplicate wells. Statistical analysis was described in sections 2.8. The analysis 
examined TNF- production by group (control vs.Trib1 knockdown), the random effect was 
the experiment and the subsets were different treatments. Log10 transformation was required, 
and p <0.05 was considered to indicate a statistically significant difference between 
experimental groups.*, p <0.05 indicates a statistically significant difference relative to the 
scrambled group. **, p <0.001; +, p <0.001 comparing the same group and different 
treatments with untreated controls. 
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4.3.3 Trib1 modulates ERK1/2 phosphorylation 
    From the literature, human Trib1 is known to associate with MAPK. For example, 
Trib1 inhibits smooth muscle cell proliferation through JNK (Kiss-Toth et al., 2004; 
Sung et al., 2007). However, Yamamoto and his colleagues reported that Trib1 does 
not regulate the MAPK pathway in mouse primary macrophages (Yamamoto et al., 
2007). To investigate a possible role for Trib1 in MAPK signalling, RAW264.7 cells 
were transfected with Trib1 or scrambled siRNA overnight and then stimulated with 
IFN- or TLR2L for 1 hr (Fig. 4.3), and then protein expression was analysed by 
western blotting. 
 
    In the scrambled siRNA group, untreated cells expressed high levels of 
phosphorylated ERK1 (pERK1) and low levels of pERK2 (p42) (Fig. 4.10A). After 
stimulation with IFN- or TLR2L, expression of pERK1 and pERK2 increased. In 
particular, pERK2 expression was higher in RAW264.7 cells stimulated with IFN- 
or TLR2L. However, ERK2 was phosphorylated to a lesser extent than was ERK1.  
 
    Following IFN- and TLR2L treatment, pERK1 expression was increased in the 
Trib1 knockdown group, although levels were lower than in the scrambled control 
group (Fig. 4.10A and B, p = 0.03, p = 0.01, p = 0.03, respectively). Moreover, 
pERK2 levels were lower in the Trib1-silenced group compared with the scrambled 
control group (Fig. 4.10A). Both IFN- and TLR2 activated ERK1/2 phosphorylation 
in scrambled and Trib1 silenced groups (p <0.001; Fig. 4.10B). 
 
   Using protein band relatively intensity to compare both groups of transfected cells, 
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the level of phosphorylated ERK1 was lower after Trib1 silencing than in the 
scrambled control group (Figs. 4.10B). 
 
    Therefore, I concluded that macrophage Trib1 positively regulates ERK1/2 
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Figure 4.10. Trib1 silencing reduces ERK1/2 phosphorylation. (A) Expression of 
phosphorylated ERK1/2 (upper band, p44/ERK1; lower band, p42/ERK2) in RAW264.7 
cells after stimulation, as determined by western blotting 60 min after treatment. Protein 
samples (55 µg) were used, as indicated in Chapter 2. Membranes were immunoblotted with 
primary antibodies specific for phosphorylated mouse ERK1/2 and total ERK1/2, and / 
tubulin was a as loading control. (B) Phosphorylated ERK1 was normalised to ɑ/β tubulin. 
Two independent experiments were carried out and the values represent the mean ± SD 
calculated from the relatively intensity normalised to / tubulin. Statistical analysis was 
described in sections 2.8. The analysis examined relative expression by group (scrambled 
vs.Trib1 knockdown), the random effect was the experiment and the subsets were the 
different treatments. p <0.05 was considered to indicate a statistically significant difference 
between experimental groups. *, p <0.05 compared with the scrambled group was considered 
to indicate statistical significance; +, p <0.001 comparing the same cell group and different 
treatments with untreated controls. 
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4.3.4 Trib1 knockdown up-regulates C/EBP expression in the presence of   
IFN-, but does not affect IL-6 production 
    Trib1 silencing leads to C/EBP up-regulation after LPS treatment in murine 
primary macrophages (Yamamoto et al., 2007). However, how Trib1 functions in 
vitro remains unclear. 
 
    In the scrambled siRNA group, untreated cells expressed low levels of C/EBP 
(Fig. 4.11A), which increased after stimulation with IFN- or TLR2L. Both IFN- 
and TLR2L induced C/EBP, especially IFN-. In the Trib1 knockdown group, 
untreated cells expressed low levels of C/EBPβ, but enhanced C/EBP expression 
was seen following treatment with IFN- or TLR2L. Interestingly, in comparison to 
the scrambled group, Trib1 knockdown increased C/EBP expression (Fig. 4.11A). 
 
    C/EBP is a nuclear factor which binds to IL-l responsive elements in the IL-6 
gene (Akira et al., 1990). Therefore, I also examined IL-6 production by ELISA. 
After in scrambled siRNA-treated RAW264.7 cells were stimulated with IFN- or 
TLR2L, IL-6 production increased compared with untreated cells (p <0.001). A 
similar result was seen in the Trib1-knockdown group (p <0.001). However, there 
was no difference between the scrambled group and the Trib1 silencing group 
following treatment (Fig. 4.11B; p >0.1), suggesting that C/EBP is not the only 






     
 
 
                    
Figure 4.11. C/EBP expression and IL-6 production in treated RAW264.7 cells. (A) 
C/EBP protein expression was determined by western blotting 60 min after different 
treatments. (B) RAW264.7 cells were treated with siRNA following stimulation with IFN-γ 
or TLR2L for 24 hr, and IL-6 secretion into culture medium was measured by ELISA. Values 
represent the mean ± SD in triplicate. Similar results were obtained from two separate 
experiments. Statistical analysis was described in sections Chapter 2.8. The same analysis 
method was used as described for Fig. 4.9.*, p <0.05 compared with the scrambled group 
was considered to indicate statistical significance; +, p <0.001 compared the same 
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    This chapter demonstrated that commercial Trib1 siRNA could efficiently 
knockdown Trib1 mRNA and aimed to validate the functional role of Trib1 in 
macrophages. The results demonstrated that Trib1 silencing results in high TNF- 
production, modulation of ERK1/2 phosphorylation and up-regulation of C/EBP 
expression. 
 
    The first objective of this chapter was to identify the Trib1 siRNA sequence 
providing the maximal efficiency of knockdown (Figs.4.4–4.8) to establish an 
optimal transfection protocol for RAW264.7 cells. Co-transfection with a GFP 
expression plasmid demonstrated efficient siRNA uptake into cells (Figs. 4.4B and 
4.7). The concentration of siRNA used is particularly important. A dose-dependent 
increase in transfection efficiency was observed with increasing siRNA at low 
concentrations, but the decreased at higher concentrations (Fig. 4.4C). The highest 
concentration of 500 nM siRNA was not selected for several reasons. Higher siRNA 
concentrations can lead to off-target effects and increased toxicity (Scherer and Rossi, 
2003). In addition, siRNAs are expensive so finding the lowest effective 
concentration is necessary. 
 
    Demonstrating the specificity of Trib1 siRNA is important, as related human genes 
contain up to 53.3% sequence homology (Trib1/Trib3), and the amino acid sequences 
between human and mouse Trib1 and Trib3 are 97.5% and 81.2%, respectively 
(Yokoyama and Nakamura, 2011). Therefore, I demonstrated that Trib1 siRNA 
specifically down-regulates Trib1 mRNA (Fig 4.8). The reduction in target gene 
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expression obtained by siRNA treatment in this study was 55%. However, due to the 
poor quality of the only available Trib1 antibody (discussed in Chapter 3), only 
mRNA knockdown data is presented. 
 
    The second part of this chapter aimed to demonstrate the biological function of 
Trib1 in RAW264.7 cells, and its interface with signalling pathways involved in the 
regulation of inflammation. 
 
    In Chapter 3, I showed that RAW264.7 cells treated with IFN- alone or in 
combination with TLR2 ligation up-regulate Trib1 transcript levels from 30 min to 6 
hr (Fig. 3.9). The MAPK signalling pathway is activated by either TLRs or IFN- 
(Gough et al., 2007; Krishnan et al., 2007), which suggests that Trib1 may regulate 
MAPK signalling in macrophages. 
 
    The majority of TNF- production is modulated by NF-B (Matsusaka et al., 
1993). Furthermore, C/EBP-mediated TNF- production in response to TLR2-
induced inflammation has been reported (Lu et al., 2009). Trib1 knockdown resulted 
in an increase of both TNF- production (Fig. 4.9) and C/EBP expression (Fig. 
4.11), consistent with a previous report indicating that C/EBP modulates TNF- 
production (Lu et al., 2009). However, there is no direct evidence to show that this 
mechanism is directly mediated by NF-B activation. 
 
    That Trib1 knockdown resulted in increased TNF- production in this study 
requires explanation. Firstly, TNF- is mainly produced by macrophages, and is a 
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potent pro-inflammatory mediator that regulates macrophage function. It is proposed 
to be a key inducer in inflammatory cell activation and in inflammatory diseases. 
Secondly, TNF- also plays a role in macrophage proliferation, differentiation and 
apoptosis. In bacterially infected tissue, macrophages become activated to secrete 
TNF- and increase endothelial adhesion to allow macrophage migration 
(Parameswaran and Patial, 2010). These observations, together with the abundant 
TNF- production caused by Trib1 knockdown, suggest that Trib1 is involved in 
macrophage function during inflammation. 
    Further, the results presented here contrast with those of Yamamoto et al. (2007), 
who reported that macrophages from Trib1-deficient mice have the same levels of 
 and TNF- production as wild type mice. A possible explanation for                
this difference is that Yamamoto’s group analysed primary cells (peritoneal 
macrophages), whereas I have used an immortalised cell line (RAW264.7 cells, 
established from a tumour induced by Abelson murine leukaemia virus; (Raschke et 
al., 1978). Similarly, while I have demonstrated that the levels of phosphorylated 
ERK1 and 2 are reduced in Trib1 siRNA-treated cells, Yamamoto et al. showed that 
Trib1-deficient macrophages had the same levels of phosphorylated MAPKs (p38, 
JNK and ERK) as normal macrophages (Yamamoto et al., 2007). However, a 
previous study of Trib1-induced murine AML suggested that cell transformation 
resulted from increased MAPK signalling (Jin et al., 2007). Consistent with the 
present study, Trib1 knockdown led to decreased ERK1/2 phosphorylation (Fig. 
4.10). Trib1 has been reported to interact with MEK1 and MKK4 (Kiss-Toth et al., 
2004). IFN- triggers activation of the MEK1/2 to ERK1/2 pathway (Gough et al., 
2007; Hu et al., 2001) and I demonstrated down-regulation of ERK1/2 
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phosphorylation by Trib1 in IFN- treated macrophages. Therefore, the MAPK 
pathway appears to be regulated by Trib1. 
 
    TLR2L activates the MAPK pathway via JNK and p38 (Akira, 2003; Krishnan et 
al., 2007); however, JNK was not detected in RAW264.7 cells. Reports from other 
groups indicate that peptidoglycan (PGN) or LPS treatment induces JNK 
phosphorylation in RAW 264.7 cells at an early time point (15 min) and that this 
decreases to baseline after 60 min (Hu et al., 2007a; Lin et al., 2010). Therefore, the 
JNK pathway may become activated early in microbial infection. I focused on the 60 
min time point, which was, in retrospect, not the best time to measure the JNK 
pathway activity. However, my results agree with Sung et al., (2006), who concluded 
that role of Trib1 in regulating signalling pathway was cell-type specific. Thus, 
RAW264.7 cells do not activate the JNK pathway following TLR2 ligand treatment 
and Trib1 is not involved in TLR2L-induced ERK1/2 phosphorylation (Fig. 4.10). 
Nonetheless, the mode of action of Trib1 in response to TLR2L-induced signalling 
remains undefined. 
 
    However, there was a small decrease in the level of ERK1 phosphorylation in 
RAW264.7 cells following treatment with TLR2L in Trib1 and scrambled siRNA 
transfected group (Fig. 4.10). Therefore, comparing the effects of IFN- and TLR2L 
stimulation reveals that IFN- induces the MAPK pathway, especially the ERK1/2, 
might be one of the Trib1 target pathways in macrophages. 
 
    I showed that Trib1 knockdown increases C/EBP protein (Fig. 4.11). This finding, 
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together with Yamamoto’s results, indicate that Trib1 inhibits C/EBP expression 
(Yamamoto et al., 2007). Slbo is a Drosophila orthologue of mammalian C/EBP 
(Rorth et al., 2000) and Drosophila Trib protein has been reported to negatively 
regulate Slbo. Thus, these combined data support the hypothesis that mammalian 
Trib1 functions to inhibit C/EBP expression in a similar way to Slbo inactivation by 
Drosophila Trib. Trib1 has been reported to regulate both C/EBP and C/EBP. 
C/EBP degradation in myeloid leukaemogenesis through Trib1/ MEK1 interaction 
(Yokoyama et al., 2010). MEK1 is the upstream regulator of ERK1/2; therefore, 
taken together with my data, it is reasonable to assume that Trib1 is also involved in 
C/EBP degradation via ERK1/2 pathway in the in vitro system. 
 
    C/EBP is a nuclear factor that specifically binds to an IL-1 responsive element in 
the IL-6 gene (the original name of C/EBPβ was NF-IL6; (Ray et al., 1989). 
However, my results showed that not only IL-6 production is regulated by C/EBP 
(Fig.4.11B) A previous report indicated that IL-6 can be synergistically activated by 
the transcription factors C/EBP and NF-B (Matsusaka et al., 1993). Nevertheless, 
there is no direct evidence for NF-B involvement in the present study. However, 
Trib1 silencing increased C/EBP expression and resulted in TNF- production. This 
may also suggest that C/EBP does not directly regulate IL-6 production in 
macrophages. 
 
    Following monocyte–macrophage differentiation, macrophages become strongly 
adherent and flattened (Gordon and Taylor, 2005). However, after Trib1 knockdown 
changes in morphology involved an increased number of rounded and detached cells 
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with monocyte-like features (Fig. 4.5D). This tempted me to speculate that that Trib1 
may have a role in the control of cell morphology. In Drosophila, the Trib orthologue 
controls timing of mitosis during mesoderm morphogenesis and changes in cell 
shape (Seher and Leptin, 2000), the latter process being regulated by Snail, a 
downstream target of Trib (Grosshans and Wieschaus, 2000; Lp and Gridley, 2002). 
Snail expression is regulated by complex signalling networks including MAPK and 
NF-B (Wu and Zhou, 2010). However, it is unclear how the Snail pathway regulates 
Trib activity to coordinate cell division and movement. 
 
    In conclusion (Fig. 4.12), in this chapter I have demonstrated that Trib1 plays a 
role in regulating the ERK1/2 and C/EBP pathways and TNF- production.    
Furthermore, Trib1 involvement in macrophage migration and other biological 




                     
Figure 4.12. Schematic illustration of the possible involvement of Trib1 in signalling 
pathways induced by IFN-γ and the TLR2 ligands in RAW264.7 cells. Trib1 functions as a 
scaffold protein linking the MEK1/ERK1/2 pathway and C/EBP. Moreover, Trib1 interacts 
with MEK1 and enhances ERK1/2 phosphorylation. Conversely, ERK1/2 inhibits C/EBP 
expression and regulates TNF- production. Up-regulated TNF- may be involved in 























Chapter 5: Investigation of novel Trib1 functions in activated 
macrophages 
Abstract 
    In Drosophila, a single Trib gene has been identified that is involved in 
morphogenesis, cell cycle progression and cell migration. Immune homeostasis is an 
important factor in immune system regulation. In particular, apoptosis is a normal 
cellular response and an important part of immune homeostasis. In gene knockdown 
experiments using Trib1 siRNA, I observed that C/EBP expression was inhibited 
and that this occurred in both stimulated (by IFN- and TLR2L) and resting murine 
macrophage populations. Moreover, expression of pERK1/2 was reduced in Trib1 
knockdown cells. The results presented in this chapter indicate that macrophages in 
which Trib1 expression is down-regulated by siRNA have altered migratory 
behaviour in response to MCP-1. Experiments examining Trib1 loss or gain of 
function show that Trib1 functions as a modulator of cell cycle transition and an 
inhibitor of apoptosis. 
    In conclusion, my data suggest that Trib1 makes a previously unrecognised 




    Trib, the only member of the Trib homologue family in Drosophila, regulates 
String/CDC25 activity and affects cell cycle progression, cell proliferation, and 
morphogenesis (Mata et al., 2000; Seher and Leptin, 2000). Moreover, the Trib gene 
is an important inhibitor of mitosis. Its biological function is to control timing during 
development and gastrulation in order to allow cell morphology changes to be 
completed (Seher and Leptin, 2000). 
    Moreover, Drosophila Trib protein negatively regulates the level of Drosophila 
Slbo, which controls border cell migration and is a fly orthologue of the mammalian 
C/EBP transcription factor (Rorth et al., 2000). In order to investigate its function, 
Slbo protein was overexpressed or the Slbo gene was deleted, leading to an absence 
of Slbo protein. These experiments showed Slbo overexpression in border cells 
delayed their migration. Thus, border cells fail to migrate properly if the level of 
Slbo protein is either too low or too high. Alternatively, Trib may form part of an 
ubiquitin E3 complex for Slbo (Bowers et al., 2003; Rorth et al., 2000). E3 
complexes are defined by their enzymatic activity, which is to stimulate transfer of 
ubiquitin from specific ubiquitin-charged E2 complexes to substrates, and can be 
unrelated in sequence (Varshavsky, 1997). Therefore, Slbo protein is degraded via 
Trib- mediated ubiquitination. 
    Cell migration is an important process related to many biological functions such as 
cell movement, shape changes and differentiation (Friedl, 2004). Cell migration can 
be classified into single cell migration (amoeboid cells) and collective migration 
modes (cell sheets, tubes and clusters). For instance, macrophage migration is 
classified as single cell migration (Friedl, 2004). 
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    Apoptosis plays a major role in the development and maintenance of all 
multicellular organisms. Moreover, apoptosis is a normal cellular response and an 
important part of immune homeostasis (Crouch et al., 1996). Macrophages play a 
central role in immune homeostasis (Henson et al., 2001). Expression of the TNF- 
receptor during Fas-induced macrophage apoptosis indicates that TNF- plays a role 
in macrophage apoptosis (Parameswaran and Patial, 2010). Trib3 is associated with 
macrophage apoptosis via the caspase-3 pathway in atherosclerosis (Shang et al., 
2009). However, the function of Trib1 in macrophage is unclear. 
    The results in Chapter 4 demonstrated that Trib1 silencing increased C/EBP 
protein expression, indicating that Trib1 inhibits C/EBP, consistent with Drosophila 
studies, and that Trib1 function may be related to cell migration via C/EBP. 
However, these potential novel functions of Trib1 remain to be verified. 
 
Aim 
    In this chapter, I sought to further investigate the biological functions of Trib1 in 
macrophages, using effective knockdown of Trib1 or Trib1 overexpression to explore 
the biological role of Trib1 in cell migration, cell cycle progression and the 









5.2 Materials, methods and experimental design 
The experimental design is summarised in Figure 5.1 but detailed methodologies are 
presented in the Chapter 2.  
             
Figure 5.1. The experimental design in this chapter. (A) Trib1 siRNA experiments 
and (B) Trib1gain-of-function experiments. 
 
 
5.2.1 Optimisation of Trib1 expression plasmid 
    Optimal conditions for transfection of the Trib1 expression into RAW264.7 cells 
were determined and transfection efficiency was measured by fluorescence 
microscopy and flow cytometry as described in section 2.3.1. Transfections were 
performed in duplicate wells of a six well plate using three different Trib1 plasmid 
concentrations (0.5 µg, 1.0 µg and 2.0 µg) and empty plasmid was used as a negative 
control. The electroporation protocol is described in detail in section 2.3.1.               
In short, RAW264.7 cells were harvest and 2×106 cells were placed into a 1.5 ml 























positive control pmaxGFP plasmid was co-transfected with the Trib1 plasmid in 
parallel by electroporation as described in section 2.3.1. Transfection efficiency was 
analysed by counting GFP-positive cells using FACS and overexpression efficiency 






5.3.1 Trib1 knockdown inhibits macrophage migration 
    In the previous chapter (Figs. 4.11A), I showed that Trib1 silencing increases 
C/EBP protein expression, indicating that Trib1 inhibits C/EBP and that Trib1 
function may be related to cell migration via C/EBP (Rorth et al., 2000). Here, I 
extend these studies and firstly investigate whether Trib1 alters macrophage 
migration. 
 
    After Trib1 knockdown overnight, chemokinesis (random movement, medium 
control) and chemokine-mediated RAW264.7 cell migration was assayed (Fig. 5.2). 
Untransfected and scrambled groups showed a standard migration pattern in the 
absence of chemokines. Reduced Trib1 expression resulted in few cells exhibiting a 
chemokinesis response (Fig.5.2A). 
 
    The addition of MCP-1 (200 ng/ml) increased the numbers of cells migrating 
toward the lower wells, particularly in the untransfected and scrambled siRNA 
groups (Fig. 5.2B). Interestingly, following Trib1 knockdown, RAW264.7 cells 
exhibited a similar migratory pattern as medium controls (Figs. 5.2A and 5.2B). 
 
    A quantitative analysis of chemokine-mediated cell migration revealed that this 
only happened in the untransfected and scrambled siRNA groups, but not in the 
Trib1-silenced group (Fig. 5.2C). Migration in the two control groups was 
significantly greater than in the Trib1-silenced group after MCP-1-treatment (p 
<0.001). However, the level of MCP-1-induced migration in Trib1 knockdown cells 
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was the same result as in controls lacking MCP-1 (p = 0.989). 
    Thus, Trib1 knockdown inhibits both chemokinesis and MCP-1 induced cell 
migration. 
              
             
Figure 5.2A. Trib1 silencing inhibits RAW264.7 cell migration. Trib1 knockdown reduced 
cell migration compared to untransfected and scrambled siRNA controls. Appearance of a 
representative micropore membrane with medium only in the lower well of the chamber. 
After 90 min, cells trapped in the filter pores or adhering to the underside of the membrane 
were fixed and stained with haematoxylin. Arrows indicate cells trapped in the pores; low 
(left, 5×) and high (right, 20×) power fields are shown. 











        
Figure 5.2B. Trib1 silencing inhibits RAW264.7 cell migration. Trib1 knockdown reduced 
cell migration compared to untransfected and scrambled siRNA controls following MCP-1 
(200 ng/ml) treatment. Appearance of a representative micropore membrane with MCP-1 
(200 ng/ml) was in the lower well of the chamber. After 90 min, cells trapped in the filter 
pores or adhering to the underside of the membrane were fixed and stained with 
haematoxylin. Arrows indicate cells trapped in the pores; low (left, 5×) and high (right, 20×) 











   
                  
Figure 5.2C. Transfilter cell migration assay showing the effect of Trib1 silencing on     
MCP-1-mediated migration. Cells were counted in in 10 randomly selected high power fields 
under microscopy (20×). Statistical analysis was determined as described in sections 2.8. 
Generalised LME models were used for the analysis of cell count data in this chapter. 
Migrated cell counts were fitted to the Poisson process. p <0.05 was considered to indicate 
statistical significance; **, p <0.001 comparing untransfected and scrambled groups with 

































5.3.2 Effect of Trib1 knockdown on cell cycle progression and apoptosis 
    Trib function in the cell cycle was first studied in Drosophila; however, whether 
Trib1 regulates the cell cycle in mammalian systems has not been investigated. Flow 
cytometric analysis of the cell cycle showed no difference in G0/G1 and S phase 
populations between the scrambled siRNA and Trib1 silenced groups up to 72 hr 
after transfection (p >0.1; Figs. 5.3A, B; Table 5.1). 
 
    Conversely, the Trib1 silencing group showed a reduction in G2/M phase 
progression from 24 hr to 72 hr relative to the scrambled siRNA group, and this 
difference reached statistical significance at the 48 hr and 72 hr time points (p = 
0.051, p = 0.028, p = 0.002, from 24 hr to 72 hr, respectively) (Fig. 5.3C, Table 5.1). 
Therefore, macrophage Trib1, similar to Drosophila, is involved in G2/M cell cycle 
progression. 
 
    A typical cell cycle distribution profile is seen in the scrambled group after 72 hr; 
in contrast, in the Trib1-silenced group after 72 hr, there was a larger proportion of 
G2 phase cells than in the scrambled siRNA group (Figs. 5.4A, B; Table 5.1). Under 
these conditions, the number of apoptotic cells (M4) was very small; consequently, a 
more accurate measurement of apoptosis was done using annexin V staining. 
 
    The numbers of late apoptotic cells (upper right, annexin V+/PI+) were 
significantly higher in the scrambled siRNA group (approximately 2 fold) than in the 
Trib1-knockdown group after 72 hr (p = 0.004) (Figs. 5.4C, D; Table 5.1). These 




Figure 5.3. Timecourse profiles of cell cycle analysis. A typical cell cycle distribution profile, 
comprising G1 phase (A), S phase (B) and G2/M phase (C), in scrambled siRNA and Trib1 
siRNA groups 0, 24, 48 and 72 hr after transfection. Data are expressed as the mean ± SD of 
two culture wells and two independent experiments. Statistical analysis was described 
section 2.8. For cell cycle analysis, the binomial process used the percentage of cells in 
G1/S/G2M phase identified by FACS sorting. The analysis examined the proportion of cells 
in G1/S/G2M phases by group (scrambled siRNA vs.Trib1 knockdown), random effects were 
defined as wells within an experiment and subsets were at different time points. p <0.05 was 
considered to indicate statistical significance; *, p <0.05; **, p <0.01 compared with the 








Scrambled siRNA Trib1 siRNA 
Binomial 
analysis 
G0/G1 67.0 ± 0.7 61.3 ± 2.1 p = 0.10
S 19.5 ± 2.0 22.0 ± 2.3 p = 0.657 
G2/M  7.8 ± 1.1 14.9 ± 0.7 p = 0.002 
Apoptosis 
(annexin V staining) 
38.0 ± 2.9 15.9 ± 4.8 p = 0.004 



































































































             
Figure 5.4. Trib1 knockdown disturbs the cell cycle and inhibits apoptosis. RAW264.7 cells 
were transfected with scrambled siRNA (A, C) or Trib1 siRNA (B, D) and examined after 72 
hr. The values in Table 5.2 represent the percentage of cells in G0/G1 (M1), S (M2), G2/M 
(M3) phases of the cell cycle. As numbers of apoptotic cells (M4) were low, annexin V was 
used to investigate changes in apoptosis (Figs. 5.4C, D). Data are represented as the mean ± 














5.3.3 Optimisation of Trib1 expression plasmid concentration for transfection 
    As Trib1 siRNA–mediated knockdown experiments suggested that Trib 1 may 
function in cell cycle progression, I next evaluated the effect of Trib1 overexpression 
of cell cycle parameters using a commercial Trib1 expression plasmid. 
 
    Trib1 expression in the empty vector control group was similar to the 
untransfected group, which was normalised to a value of 1 (100%) (Fig. 5.5). 
RAW264.7 cells were transfected with increasing amounts of Trib1 vector. Relative 
Trib1 expression increased by 50% following transfection with 0.5 µg vector 
(significance, p <0.001). However, when the amount of Trib1 vector was increased 
from 1.0 µg to 2.0 µg, relative Trib1 expression failed to increase over the baseline 
levels in the vector control group (1.0 µg DNA, p = 0.057) or was lower than the 
vector control group (2.0 µg DNA, p = 0.001; Fig. 5.5). Therefore, the 0.5 µg of 
Trib1 vector was used for subsequent Trib1 overexpression experiments. 






            
Figure 5.5. Optimisation of Trib1 plasmid concentrations for transfection. Trib1 expression 
was measured by qPCR. The values represent the mean ± SD of two separate experiments. 
Statistical analysis was described in sections 2.8. LME methods were used for statistical 
analysis. Fixed effects were defined as vector control for the comparison of three Trib1 
plasmid concentrations and random effects were defined as wells within an experiment. This 
data required Log2 transformation to normalise the residuals before analysis. A standard 
post-hoc (Tukey) test was used to carry out pair-wise comparisons of all groups. In all cases, 
p <0.05 when comparing experimental groups was considered to indicate a statistically 
significant difference.* p <0.05 compared with the vector control group was considered to 
indicate statistical significance; ** p <0.001. 
 
     











































    The same experimental design was used as described for the siRNA-mediated 
gene knockdown experiment. Twenty-four hr after transfection, the proportion of 
live cells in the vector control and Trib1-transfected groups were 45.5% and 28.8%, 
respectively (Figs. 5.6A, B). 
 
    As there were more dead cells in the Trib1-transfected group, the cell cycle was 
only assessed at 24 hr and the time points for assaying apoptosis were 6 hr and 24 hr. 
     
 
 
Figure 5.6. Viability of Trib1 transfected cells. PI staining and FACS were used to examined 
the viability of RAW264.7 cells 24 hr after transfection with (A) empty vector control and (B) 
Trib1 expression vector. M1 represents the live cell population. Two separate experiments 







5.3.4 Effect of Trib1 overexpression on cell cycle progression and apoptosis 
    The experimental design of Trib1 overexpression was referred to Fig. 5.1B. In 
contrast to the Trib1 knockdown data, Trib1overexpression resulted in a significant 
accumulation of cells in the G1 phase, and a reduced proportion of cells in the S and 
G2/M phases compared to the vector control group (Table 5.2 and Fig. 5.7C). The 
empty vector controls showed the same cell cycle profiles as untreated RAW264.7 
cells (Table 5.2, Figs. 5.7B and A, respectively). Thus, excess Trib1 causes 
macrophages to arrest at the G1 transition. 
 
Table 5.2. Cell cycle analysis of RAW264.7 cells 24 hr post-transfection 
Cell phase (%) Empty vector  





G0/G1 63.04 ± 0.3 74.46 ± 0.9 p = 0.045
 
S 18.31 ± 1.0 15.18 ± 1.0 p = 0.613 
G2/M 12.19 ± 0.2  7.31 ± 0.6 p = 0.17 




Figure 5.7. Trib1 overexpression disturbs the cell cycle. Untreated RAW 264.7 cells (A) and 
cells transfected with empty vector control (B) or Trib1 expression vector (C) after 24 hr. 
The values in Table 5.2 represent the percentage of cells in G0/G1 (M1), S (M2), G2/M (M3) 










    I previously showed that Trib1 silencing postpones RAW264.7 cell apoptosis after 
72 hr (Figs. 5.4C, D). I compared over- and under-expression of Trib1 in RAW264.7 
cells at 6 hr and 24 hr after transfection. After 6 hr, there was no significant increase 
in apoptosis in either gain-of-function or knockdown experiments (Table 5.3, upper 
row). Numbers of apoptotic cells were much higher in the Trib1 overexpression 
group than in the empty vector at 24 hr and this was statistically significant (Fig. 
5.8A, B; Table 5.3, lower row; p = 0.031). However, there was no difference in 
apoptosis levels in the Trib1 knockdown experiment after 24 hr (Fig. 5.8C, D; Table 
5.3, lower row; p = 0.157). 
 
    Interestingly, comparing 6 hr and 24 hr time points in the Trib1 overexpression 
groups showed a significant increase in apoptosis in Trib1 plasmid groups but no 
significance in the empty vector controls (p = 0.001 and p = 0.064, respectively). 
Nevertheless, There was no significant difference in apoptosis levels in the Trib1 
knockdown group between 6 and 24 hr (p >0.1). 
 
    Conversely, compared with the gain-of-function experiment, levels of apoptosis in 
the Trib1 siRNA group decreased after 24 hr (Table 5.3; Fig. 5.8B and D;  p <0.001). 





Table 5.3. Levels of apoptosis in RAW264.7 cells 6hr and 24 hr post-transfection 

























p = 0.395 47.2 ± 0.9 
48.7 ± 
0.2 







p = 0.031 54.5 ± 1.9 
47.1 ± 
1.4 
p = 0.157 
*Compared with the vector control group; ** compared with the scrambled control 




Figure 5.8. The effect of Trib1 gain- or loss-of-function on apoptosis levels. RAW264.7 cells 
were transfected with (A) empty vector, (B) Trib1 expression plasmid, (C) scrambled siRNA 















    The finding that reduced expression of Trib1 in RAW264.7 cells results in reduced 
cell adhesion (Chapter 4), prompted me to investigate the biological function of 
Trib1 in macrophage recruitment /migration. By overexpressing or reducing levels of 
Trib1, I demonstrated that Trib1 has an influential role in macrophage migration, 
G2/M transition and delaying apoptosis. 
 
    It was reported that Trib negatively regulates Slbo in Drosophila cell migration 
(Rorth et al., 2000). Here, I have also demonstrated that diminished expression of 
Trib1 reduces macrophage migration (Fig. 5.2). MCP-1, also named CCL2, is a key 
chemokine in regulating the recruitment and migration of monocytes/macrophages to 
sites of active inflammation (Ajuebor et al., 1998; Sozzani et al., 1993). In the 
untransfected and scrambled siRNA groups, MCP-1-treated macrophages showed 
strong chemokinesis activity. However, the numbers of migrating macrophages were 
unchanged in the Trib1-silenced group. Thus, this result suggests that Trib1 
expression is associated with macrophage migration. Moreover, this result is 
consistent with a report that suppression of human Trib2 protein in melanoma cells 
decreases cell migration (Zanella et al., 2010). Furthermore, MCP-1 activates the 
p42/p44 MAPK pathway (Sodhi and Biswas, 2002) and my results showed that Trib1 
regulates ERK1/2 and inhibits C/EBPβ expression (Fig. 4.10 and Fig. 4.11). A 
previous report indicating that Trib1 functions as an adaptor between the ERK 
pathway and C/EBP degradation also support my data (Yokoyama et al., 2010). 
Collectively, the published literature together with my observations suggests that 
Trib1 regulates macrophage migration via the p42/44 MAPK (ERK1/2) pathway and 
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C/EBP inhibition in response to MCP-1 in vitro. Therefore, in this chapter, I 
demonstrated that loss of Trib1 is associated with macrophage dysfunction, such as 
in reduced migration. 
 
    As demonstrated in Chapter 4, a consequence of Trib1 silencing is altered 
macrophage morphology (Fig. 4.5C, D). It is unclear how this result relates to studies 
in Drosophila, although the link may be through Trib1 altering Snail expression or 
signalling (Grosshans and Wieschaus, 2000). Snail protein is a marker of 
macrophage migration during inflammation and early wound healing (Hotz et al., 
2010), which raises the possibility that Trib1 modulates cell migration through its 
interaction with Snail. 
 
    Multiple signalling pathways, such as Akt and MEK1/MKK7 (MAPK), can induce 
macrophage apoptosis, and Trib3 has been reported to have the same function 
(Fernández-Hernando C, 2007; Han S, 2006; Shang et al., 2009). Moreover, Trib3-
silenced macrophages showed decreased apoptosis (Shang et al., 2009), consistent 
with my result for Trib1. In the present study, I demonstrated that Trib1 reduced the 
apoptotic of macrophages (Fig. 5.4C, D; Table 5.1). It is reasonable to suggest that 
Trib1 has a novel role in protecting from cell death, similar to Trib3. Moreover, Trib1 
has been suggested to influence cell proliferation in human vascular smooth muscle 
cells and Trib3 has a similar function in macrophage (Shang et al., 2009; Sung et al., 
2007). Hence, Trib1 may influence macrophage proliferation. In order to confirm this 




    Not surprisingly, overexpression of Trib1 caused a marked increase in apoptosis. 
This finding is similar to Trib3 overexpression, which caused an increase in apoptotic 
macrophages (Shang et al., 2009). Here, I examined two time points, 6 hr and 24 hr, 
in the gain-of-function experiments. Even with the vector control, it was clear that 
electroporation killed approximately 50% cells after 6 hr. Furthermore, analysis of 
GFP expression (data not shown) showed that gene expression had not occurred to 
detectable levels in RAW 264.7 cells by 6 hr, therefore, confirming that the early 
apoptosis was due to the electroporation technique. Additionally, there was no 
significant increase in apoptosis in the vehicle controls (empty vector and scrambled 
siRNA, p >0.1). However, 24 hr after transfection, Trib1 overexpression induces 
apoptosis and a reduced expression of Trib1 leads to reduced apoptosis (Table 5.3). 
Signal transduction pathways that control apoptosis in macrophages are complex. 
Therefore, my results suggest that Trib1 may control macrophage apoptosis as Trib3 
does (Shang et al., 2009). The precise mechanism needs to be evaluated in the future. 
 
    In Drosophila, Trib acts as a brake on the cell cycle, especially at the G2/M 
transition phase (Seher and Leptin, 2000). Furthermore, Trib3 can slow cell cycle 
progression in G2/M in human T cells (Selim et al., 2007). Interestingly, Trib1 
silencing had the same result (Fig. 5.4B; Table 5.1), but Trib1 overexpression 
resulted in G1 arrest (Table 5.2; Fig. 5.7C). Although my Trib1 overexpression data is 
inconsistent with the fruit fly study, it was consistent with the report that Snail 
overexpression results in G0/G1 arrest (Vega et al., 2004). Therefore, it can be 
concluded that Trib1 and Snail have similar functions in controlling the cell cycle. 
Furthermore, there are discrepancies between this study and those reported for 
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Drosophila Trib. For example, Trib1 activity may be cell-type specific (Kiss-Toth et 
al., 2004; Sung et al., 2006). 
 
    However, why are gain and loss of function results contradictory? It is possible 
that high expression of the Trib1 protein due to the CMV promoter cannot be 
efficiently post-translationally modified and that the excess Trib1 protein results in 
cell cycle disruption. 
 
    In summary, I have shown that Trib1 plays a role in the regulation of macrophage 
function. Trib1 silencing in macrophages causes a loss of migration (Fig. 5.2), delays 
cell entry into G2/M and delays apoptosis (Figs. 5.3, 5.4 and 5.8). Combined with the 
results from Chapter 4, a novel role is postulated for Trib1 in modulation of ERK1/2 
phosphorylation in macrophages (Fig. 4.10), as well as in C/EBP inhibition (Fig. 
4.11) to modulate downstream functions, such as migration (Fig. 5.9). 
 
     In conclusion, this chapter achieved the aim of demonstrating that Trib1 displays 













Figure 5.9. Schematic illustration of the possible signalling pathways interacting with Trib1 
in RAW264.7 cells. Trib1 functions as a scaffold protein linking the MEK1/ERK1/ERK2 
pathway and C/EBP. MCP-1 induces ERK1/2 phosphorylation and triggers chemokinesis. 
Trib1 interacts with MEK1 and enhances ERK1/2 phosphorylation that might control cell 
migration. Conversely, ERK1/2 inhibits C/EBP and Trib1 medicates cell movement. 
Further, Trib1 plays a role in modulating the cell cycle in macrophages by inducing G2/M 















Chapter 6: General discussion 
6.1 Introduction 
    When Trib was identified in Drosophila, it was reported to function as a regulator 
of the cell cycle, cell proliferation, and morphogenesis (Mata et al., 2000; Seher and 
Leptin, 2000). In mammalian systems, more specific functions have been 
demonstrated for Trib2 and Trib3, such as the contribution of Trib2 to AML and 
human lung cancer through C/EBP down-regulation (Dedhia et al., 2010; 
Grandinetti et al., 2011; Keeshan et al., 2010; Keeshan et al., 2006; Keeshan et al., 
2008). Trib3 function is connected with nutrient metabolism (Du et al., 2003; 
Iynedjian, 2005; Koo et al., 2004; Okamoto et al., 2007; Qi et al., 2006), and both 
Trib2 and Trib3 are involved in atherosclerosis (Deng et al., 2009; Shang et al., 
2009). Compared with Trib2 and Trib3, there is very little information on the role of 
Trib1. Although the major functions of Trib1 remain unclear, possible roles for Trib1 
have been discovered in this thesis. 
 
    In the in vivo system, it was demonstrated that Trib1-deficient female mice are 
infertile (Yamamoto et al., 2007). Moreover, female fruit flies overexpressing Trib 
have smaller ovaries with fewer egg chambers than wild-type flies (Mata et al., 
2000). Trib1 knockdown in macrophages in vitro does not cause cell death (Fig. 
4.6D). Thus, although absence of Trib1 causes female infertility, these results 
indicate it is a non-essential protein. 
 
    My observations in Chapters 4 and 5 show that silencing macrophage Trib1 up-
regulates TNF- production following treatment with immune modulators (Fig. 4.9) 
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and that macrophage migration is inhibited via ERK1/2 and C/EBP regulation (Figs. 
4.10 and 4.11). 
 
    In the innate immune response, macrophage functions include phagocytosis and 
antigen presentation to activate T cells (Janeway et al., 2001). Therefore, migration 
of macrophages to inflammatory tissue is necessary. However, Trib1-deficient 
macrophages failed to migrate, so I suspect that Trib1 protein influences macrophage 
migration (Fig. 5.2). This result is consistent with the fruit fly study, which indicated 
that Drosophila loss of Trib down-regulates border cell migration (Rorth et al., 2000). 
 
    Here, I demonstrated that the murine Trib1 displays similar functions to that of 
fruit flies, such as controlling G2/M transition (Figs. 5.3C, 5.4B). Moreover, Trib1 
delayed apoptosis in macrophages (Figs. 5.4C and D) as was previously reported for 
human Trib3 (Shang et al., 2009). Further, loss of macrophage function during 
inflammation leads to disease, including atherosclerosis. Although I do not provide 
enough evidence to verify the relationship between Trib1 and atherosclerosis, my 
findings suggest that a link may exist. Thus, I suggest that Trib1 has a potential role 
in atherosclerosis and future experiments will aim to investigate this possibility. 
 
    There are inconsistencies between my present results and those reported for 
Drosophila Trib and by Kiss-Toth’s group. The unique feature of mammalian Trib 
proteins is that they are cell-type specific; therefore, similar treatments may have 
contrasting results in different tissues (Kiss-Toth et al., 2004; Sung et al., 2006). I 
found this characteristic in my apoptosis and cell cycle experiments (Figs. 5.3, 5.4, 
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5.7 and 5.8). The present study showed G2/M arrest in Trib knockdown cells and 
delayed G1/S following Trib1 overexpression (Fig. 5.7). These findings contradict 
those of Drosophila Trib. However, Kiss-Toth’s group found no effect on cell cycle 
progression in HeLa cells by either overexpression or with antisense silencing of 
either Trib1 or Trib3. Further evidence suggests that Trib1 function following 
overexpression in primary bone marrow derived macrophages (BMMs) (Yamamoto 
et al., 2007) and immortalised macrophage cell line are different (Chapter 4). 
Therefore, my results also demonstrate that Trib1 expression is cell-type specific. 
 
    TNF- is a pro-inflammatory cytokine with an important role during inflammation. 
It is released quickly after infection and is an early mediator in inflamed tissue 
(Parameswaran and Patial, 2010). In this study, Trib1 knockdown caused up-
regulation of TNF- after stimulation with IFN- or TLR2L (Fig. 4.9). A study using 
Trib1 knockout mice demonstrated that Trib1 is a pro-inflammatory gene that 
regulates TNF- production and controls NF-B activity (Ostertag et al., 2010). This 
information provides strong evidence to support my findings of Chapter 4. However, 
TNF- is also associated with macrophage apoptosis (Flad et al., 1999). My 
observation of increased TNF- production associated with delayed apoptosis 
following Trib1 knockdown indicates that the Trib1-induced delay in macrophage 
apoptosis is TNF- independent. 
 
    Overall, Trib1 functions and my research findings have been fully discussed in the 
previous chapters of this thesis. In addition to the aforementioned functions, I would 
like to propose three possible roles for this novel protein in the following sections. 
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6.1.1 Trib1 signalling pathways 
    Kiss-Toth’s group was the first to propose an interaction between Trib and certain 
signalling pathways, mainly the MAPK pathway. Both Trib over- and under-
expression were reported to inhibit MAPK. Firstly, Trib3 interacts with the MEK1 
and MKK7 upstream components of the MAPK pathway (Kiss-Toth et al., 2004). 
Secondly, Trib2 negatively regulates MEK1 and MKK7 in monocytes (Eder et al., 
2008). My study confirmed that Trib1 positively regulates ERK1/ERK2 (MAPK) and 
downstream biological functions, such as macrophage migration (Fig. 5.2). Moreover, 
Trib1 inhibits C/EBP through an ERK1/ERK2 (MAPK) interaction (Figs. 4.10 and 
4.11), consistent with Yokoyama’s findings (2010). Furthermore, Trib2 has been 
reported to negatively regulate the C/EBP family via its conserved C-terminal-
binding site for the E3 ubiquitin ligases (COP-1; (Keeshan et al., 2010; Keeshan et 
al., 2006). Surprisingly, Trib3 regulates lipid metabolism through the same pathway 
(Qi et al., 2006), and the COP-1 binding motif is conserved in the C-terminus of all 
three mammalian Trib proteins. However, the results obtained in the current study do 
not provide direct evidence that Trib1 uses the same mechanism to regulate C/EBP. 
Taken together, all three members of Trib function as inhibitors of the C/EBP family. 
A report proposed that Trib1 is a scaffold protein between the MEK/ERK1/2 pathway 
and C/EBP (Yokoyama and Nakamura, 2011), which supports my hypothesis. A 
series of downstream cellular events are triggered by Trib1 interaction with ERK1/2 
and C/EBP, resulting in cell migration (Chapter 4). Whether or not Trib1 is 
involved in Akt and Notch pathways is unclear; however, some preliminary results 
indicated that Trib1 might be a downstream target of Notch pathway in RAW264.7 
cells treated with -secretase inhibitors (GSIs). Table.6.1 summarises the signalling 
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pathways in which Trib1 is involved. 
 
Table. 6.1. Summary of potential Trib1 signalling pathways identified in this thesis 
 Trib1 
MAPK 
MEK1/MKK4 (Kiss-Toth et al., 2004) 
a regulator of ERK1/2 (Chapter 4) 
C/EBP 
Inhibition (Yamamoto et al., 2007) 
Inhibition (IFN- induced, Chapter 4) 
 
May be an inhibitor 
(Chapter 4, indirect evidence from the TNF- production) 
Akt 
Akt expression was very weak in RAW264.7 cells 
(preliminary results) 
Notch 
May be a downstream target 
(GSIs were treated, preliminary results) 
 
6.1.2 Diverse roles for Trib proteins in cell differentiation and de-differentiation 
    Trib1 and Trib2 function with HoxA9/Meis1 to induce AML (Jin et al., 2007; 
Keeshan et al., 2008). The Hox gene has a key role in haematopoiesis and regulates 
myeloid differentiation. Moreover, Trib1 is associated with early cell differentiation 
and has been reported to be involved in mammary epithelial cell differentiation 
(Perotti et al., 2009). The possibility that Trib1 may have a role in differentiation 
prompts me to speculate that Trib1 may be associated with stem cell function. 
Interestingly, a recent report that human Trib2 may have a role in cancer stem cells 
supports this hypothesis (Grandinetti et al., 2011). 
 
    RAW264.7 cells were used in the current study; however, my results using these 
cells differed from Yamamoto’s findings in bone marrow derived macrophages. An 
explanation for this discrepancy may be that cell lines are relatively differentiated 
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and that Trib1 modulates downstream signalling pathways, such as ERK1/2, in 
activated macrophages (Fig. 4.11). Furthermore, bone marrow derived macrophages 
are classified as primary cells that may not be well differentiated; therefore, Trib1 
may not function in regulating the MAPK pathway in these cells. As discussed in 
section 6.1, Trib1 plays diverse roles in different tissues. Drosophila studies reported 
contradictory results to my current study due to differences in developmental stage, 
i.e. developing vs. differentiated. Thus, it may be worthwhile examining the role of 
Trib1 in differentiation or in undifferentiated cells, such as stem cells or cancer stem 
cells, in the future. 
 
6.1.3 The epithelial–mesenchymal transition and tumour-associated 
macrophages 
    After Trib1 siRNA electroporation and overnight culture, RAW264.7 morphology 
had changed to exhibit mainly monocyte-like features (Fig. 4.5D). Snail is involved 
in different stages of development, including the control of cell shape (Hemavathy et 
al., 2000). Overexpression of Snail increases ERK1/2 activity (Vega et al., 2004), 
consistent with Trib1 knockdown data in Chapter 4. Trib1, through its interaction 
with Snail, may modulate cell motility and cell cycle progression, and delay 
apoptosis by regulating ERK1/2. 
 
    The EMT is a fundamentally important, reversible cellular event that occurs during 
development and wound healing. It allows tightly anchored epithelial cells to lose 
their cellular adhesion and acquire migratory and invasive properties (Thiery et al., 
2009). Further, Snail transcriptional activation has a significant role in triggering 
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EMT (Kalluri, 2009; Thiery and Sleeman, 2006). EMT is a key step in cancer 
metastasis (Radisky, 2005). The morphology of Trib1 knockdown macrophages has 
some features in common with “EMT-like” cells (Table 6.2), although RAW264.7 
cells are not epithelial cells. Features of Trib1-silenced cells are therefore similar to 
“EMT-like” features (caused by increasing Snail expression). Thus, it would be 
exciting to understand how Trib interacts with Snail. Intriguingly, Snail has been 
reported to mediate the migration of activated macrophages during TGF--induced 
inflammation and wound healing (Hotz et al., 2010). I therefore speculate that Trib1 
may function in the EMT through Snail. 
 
Table 6.2. Comparison of Trib1 silencing cell features and EMT-like features (caused 
by increased Snail expression) 
 
EMT-like features 
(overexpression of Snail in 
murine melanoma cell line)
(Kudo-Saito et al., 2009) 
Trib1 silencing features 
in murine macrophages 
(my findings) 
Cell shape Spindle, dendritic like Round, monocyte-like 
Cell proliferation Decreased NDab 
Cell adhesion Decreased Decreased 





a, experiment has not been done; b, decreased apoptosis in Trib1-silenced cells. 
 
 
    As tumours progress, however, macrophages receive further differentiation signals, 
perhaps from the tumour itself, and begin to produce anti-inflammatory cytokines. 
TAMs and their anti-inflammatory cytokines can induce a series of 
immunosuppression signals that prevent tumour rejection. Thus, in cancer, the 
responses of macrophages to their microenvironment can determine disease 
progression (Mosser, 2003). 
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    Trib1 has been reported to be a myeloid oncogene (Jin et al., 2007). My results 
using a macrophage cell line did not clarify whether macrophage function in this cell 
line was different from primary macrophages. For instance, the adherence of 
following Trib1 silencing, RAW264.7 cells become less and less than the scrambled 
siRNA group. Therefore, these cells may have transformed into an undefined type of 
macrophage, which have lost typical macrophage characteristics, such as migration 
(Chapter 5), adhesion and cell shape (Chapter 4). Yamamoto’s microarray results 
indicate that prostaglandin E synthase, lipocalin-2 (24p3), arginase type II and 
plasminogen activator inhibitor type II were highly up-regulated in Trib1-deficient 
macrophages (Yamamoto et al., 2007), and this phenotype is similar to that of M2 
macrophages. However, the classification of TAMs is more specifically M2c type 
(Mantovani and Sica, 2010; Mantovani et al., 2002; Sica et al., 2008). This evidence 
indicates that Trib1 deficiency induces macrophages to develop a TAM-like 
phenotype. IL-10 treatment in vitro leads to the development of an M2c phenotype 
and deactivates macrophages (Mantovani et al., 2004). An attractive hypothesis 
suggests that C/EBP influences macrophage polarisation to form TAMs (He et al., 
2009), and my results demonstrate that Trib1 knockdown causes enhances C/EBP 
expression. Therefore, Trib1 might be involved in TAMs differentiation through 
C/EBP. TAMs are key producers of TNF- (Pollard, 2004). Interestingly, I found 
that Trib1-silenced macrophages stimulated by TLR2L/IFN-  produced higher levels 
of TNF- that controls (Fig. 4.9). Although the present study did not include further 
experiments to observe the phenotype of Trib1-defiencent macrophages, if Trib1 is 
involved in transforming normal macrophages into TAMs, it may become a 
biomarker for use in tumour immunology. Manipulating the responses of Trib1 may 
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provide a therapeutic tool to reverse or prevent diseases. 
 
    Finally, the following illustration is proposed to summarise the role of Trib1 in 
activated macrophages (Fig. 6.1). 
               
Figure 6.1. The proposed mechanism of Trib1 function in activated macrophages. When 
macrophages are activated by bacteria or inflammatory cytokines, Trib1 either interacts with 
ERK1/2 or directly inhibits C/EBP expression, resulting in downstream events, such as 
TNF- production. Furthermore, Trib1 regulates a series of macrophage functions, such as 
















6.2 Future work on Trib1 
    In this thesis, I left some important unanswered questions regarding direct 
evidence for Trib1 in C/EBP regulation, the relationships between Trib1 and EMT, 
and also between Trib1 with TAMs. Additionally, the disease profiles of bacterial 
infection should be investigated as Smith et al. (2011) have done for Trib3. Moreover, 
direct evidence of a role for Trib1 in atherosclerosis should be defined. The most 
significant and remarkable question of all will be whether Trib1 is involved in EMT. 
If Trib1 has a role in EMT, Trib1 could be a new therapeutic target for the prevention 
of cancer progression or metastasis in tumour immunology. Furthermore, Trib1 is 
also reported to be expressed in human CD4+CD25+ regulatory T cells (Pfoertner et 
al., 2006). A lack of Treg cells that express CD4+CD25+ results in severe 
autoimmunity in both mice and humans (Buckner, 2010). Therefore, it will be 
worthwhile exploring the functional role of Trib1 in autoimmune diseases. Finally, 
all studies in this thesis were done using RAW264.7 cells; however, it would be 
useful to verify Trib1 function in primary BMMs. As Trib1 is a myeloid oncogene, 
Trib1-silencing in primary BMMs may provide more compelling evidence of Trib1 
function. This would provide a comprehensive assessment of the roles of Trib1 both 




     
                   
Figure 7.1. Expression of Tribs transcripts in splenocytes. The expression profiles of Trib1 
(lane 1; 294 bp), Trib2 (lane 2; 221 bp) and Trib3 (lane 3; 246 bp) transcripts were check that 
all Tribs primers were functional. A housekeeping gene (GAPDH, 472 bp) was used as an 















Solutions and buffers 
Agarose gels: 2% small (35 ml) and large gels (100–120 ml) are made by adding 2g 
agarose to 100 ml 1× TAE buffer and heating by microwave until dissolved. The 
solution is allowed to cool, and nucleic acid labelling solutions are added before the 
agarose solution is poured into moulds and allowed to set. 
 
-phosphatase inhibitor: 1 M β-phosphatase (β-GPP, Merck, MW= 306.1). -GPP 
(15.3 g) is added to 50 ml dH2O to make a 1 M solution. Then, 1 ml of 1M -GPP 
solution is added to 100 ml blocking solution or PBS and final concentration is 
10mM. 
 
Freezing medium: 10% DMSO in FBS 
 
Luria broth base (Miller’s LB broth base, Invitrogen): Powder (25 g) is dissolved 
in 1 L of distilled water, autoclaved and allowed to cool. Ampicillin (250 µl) at a 
concentration of 100 mg/ml is added to 250 ml LB broth. Typical formula per litre: 
10 g Peptone 140, 5 g Yeast Extract, 10 g NaCl. 
 
Phosphate-buffered saline (PBS) (10x): Purchased as 10× concentrate and is made 
up to a 1× solution by adding 100 ml 10× solution to 900 ml distilled water. Typical 
formula per litre: 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4 and 0.24 g KH2PO4. 




PBST blocking buffer: 5% (w/v) skimmed milk powder in PBST. 
 
Propidium Iodide: A 10 mg/ml stock solution is made in water and stored in 20 μl 
aliquots at ˗20°C. The working solution of 200 μg/ml is made by adding 980 μl PBS 






dH2O 3.3 ml 
30 %, 37.5:1 Ratio Acrylamide/Bis-acrylamide 
(Protigel) 
4.0 ml 
1.5 M Tris, pH 8.8 2.5 ml 
10 % SDS 100 μl 
10 % Ammonium persulphate (APS)(Sigma, UK) 100 μl 
N, N, Nʹ, Nʹ-tetramethylethylenediamine 
(TEMED)(Sigma, UK) 
5 μl 
Total (For 2 gels) 10 ml 
 
SDS sample Buffer (2×): 120 mM Tris-HCl pH 6.8, 4% (w/v) SDS, 20% (v/v) 
glycerol, 200 mM DTT, 0.04% (w/v) bromophenol blue. 
 
SDS-PAGE running buffer (5×) 
Ingredient  
Trizma base (Sigma, UK) 125 mM 
Glycine (Sigma, UK) 1.25 M 
SDS (Sigma, UK) 0.5 % 
Add dH2O to final volume 1 L 






dH2O 2.77 ml 
30%, 37.5:1 Ratio Acrylamide/Bis-acrylamide 
(ProtiGel) 
830 μl 
0.5 M Tris, pH 6.8 1.26 ml 
10% SDS 50 μl 
10% APS 50 μl 
TEMED 5 μl 
Total (For 2 gels) 5 ml 
 
TAE electrophoresis buffer (50×) 
Ingredient  
Trizma base (Sigma, UK) 2 M 
Glacial acetic acid (Sigma, UK) 1 M 
EDTA (Sigma, UK) 50 mM 
Add dH2O to final volume 1 L 
 Adjust to pH 7.0 
 
Transfer buffer (1x) 
Ingredient  
Trizma base (Sigma, UK) 25 mM 
Glycine (Sigma, UK) 192 mM 
20% (v/v) methanol 200 ml 





Tris-buffered saline (TBS, 1×): 20mM Tris-HCl, 0.15M NaCl. 
 
Tris-buffered saline Tween-20 (TBST): 20mM Tris-HCl, 0.15M NaCl, 0.1% 
Tween-20. 
 
TBST blocking buffer: 5% 5% (w/v) skimmed milk powder in TBST. 
 
Western blotting enhanced chemiluminescence (ECL) detection solution: 
Solution 1 
Ingredient  
250 mM Luminol (Sigma, UK) 1 ml 
90 mM Coumaric acid (Sigma, UK) 440 μl 
1M Tris, pH 8.5 10 ml 




30 % Hydrogen peroxide 
(H2O2)(Sigma, UK) 
64 μl 
1M Tris, pH 8.5 10 ml 
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